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ABIN1 IN THE PATHOGENESIS OF GLOMERULONEPHRITIS AND THE NOVEL 
PODOCYTE-NEUTROPHIL PROINFLAMMATORY AXIS 
Erik Anderson Korte 
April 8th, 2016 
  
Glomerulonephritis (GN) is the most common cause of end-stage renal disease 
worldwide and is characterized by deposition of immune complex, inflammation, 
proteinuria and podocyte damage.  Immunosuppressive therapy is effective in less than 
50% of patients, indicating that immunological activity is not the only relevant cause of 
kidney injury.  While methods have been described for neutrophil-mediated immune 
activation, specific glomerular mechanisms for recruitment of neutrophils and 
development of GN have not been determined.   
Here I present a pathogenic mechanism for the development of GN involving a 
novel podocyte-neutrophil axis and reveal the importance of glomerular NF-κB inhibition 
by the ubiquitin binding protein, ABIN1.  I implicate enhanced glomerular NF-κB 
activity in human chronic kidney disease using transcriptomic analysis and link genetic 
ABIN1 polymorphisms to increased risk of lupus-related GN.  Mice expressing 
dysfunctional ABIN1 with disrupted polyubiquitin binding activity are shown to develop 
spontaneous, progressive glomerular disease.  Prevention and early diagnosis require an 
vii 
understanding of the initiating steps of disease pathogenesis, so early pathogenic changes 
were examined using antibodies directed against the mouse glomerular basement 
membrane to induce rapid glomerular damage.  Glomeruli of mice expressing 
dysfunctional ABIN1 exhibit increased production of NF-κB target cytokines and rapid 
induction of GN versus wild type mice.  Bone marrow transplantation reveals the 
glomerular genotype is more critical than the immune genotype following insult, further 
supporting the role of the target tissue in early disease pathogenesis.  I outline the 
contributions of mass spectrometry to the discovery of modulating factors and disease 
biomarkers in autoimmunity and describe an optimized technique to characterize the 
secreted protein milieu of cultured human podocytes.  Dysfunctional ABIN1 results in 
enhanced cytokine production by podocytes that can recruit and activate primary 
neutrophils.   Further, the podocytes are more sensitive to pathogenic cytoskeletal 
remodeling following exposure to neutrophil granules, highlighting a reciprocal injurious 
mechanism.  Finally, a novel peptide inhibitor of neutrophil granule release attenuates 
antibody-induced proteinuria in these mice and may have therapeutic potential in human 
GN.  Thus, I describe a novel podocyte-neutrophil axis in the pathogenesis of GN and 
propose a potential molecular mechanism of GN involving loss of ABIN1 function 
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BACKGROUND AND INTRODUCTION 
 
 
1.1 – Overview 
 
 The basic role of the kidney is to provide selective filtration of blood for removal 
of wastes, homeostatic maintenance of vascular solutes, and regulation of blood volume.  
Together, the kidneys receive roughly 25% of cardiac output.  This high rate of perfusion 
is required for optimal renal function and reduction in the glomerular perfusion results in 
reduced renal function.  The renal arterial vasculature terminates at a small ball of 
capillaries termed the glomerulus which is where initial filtration takes place.  Damage to 
the glomerulus results in protein and/or whole cell loss into the urine and reduced renal 
function [1].  Glomerulonephritis (GN) is a term which represents a heterogeneous group 
of diseases which accounts for 20% of chronic kidney diseases and is the leading cause of 
end-stage renal disease (ESRD) worldwide, although it ranks third in the United States 
behind diabetes and hypertension [2].  While GN is rather rare, unlike diabetes and 
hypertension, it predominantly affects young people and results in a lifelong medical 





 Many of the conditions clustered under the grand title of GN share a similar 
etiology, that is, deposition of antibodies within the glomerulus.  These circulating 
antibodies may deposit in the glomerulus through passive means with low or no direct 
affinity to the glomerular structures, which is the case in Lupus Nephritis (LN) and IgA 
nephropathy[1,3,4].  In some cases, these antibodies are specific for glomerular 
structures, as in Goodpasture disease as well as membranous glomerulonephritis 
(formerly “Idiopathic” GN before identification of the Phospholipase A2 receptor as the 
autoantigenic target of membranous glomerulonephritis in our lab in 2009) [5–7].   
It can be argued that the archetypical autoimmune condition throughout medical 
history is systemic lupus erythematosus (SLE), characterized by an abnormal immune 
response leading to loss of self-tolerance, autoantibody production, immune complex 
formation, T cell activation, and inflammatory cytokine release [8]. Medical historians 
note writings by Hippocrates that refer to the condition, but it was not until the late 
1800’s and early 1900’s when it was described in the modern sense [9].  Multiple factors 
contribute to the immune response in SLE including genetic, epigenetic, 
immunoregulatory, environmental, and hormonal factors [8,9]. SLE has the ability to 
affect essentially any body tissue, including the kidney.   
Lupus nephritis (LN) occurs clinically in about 50% of patients with SLE and is a 
major cause of morbidity and mortality [10]. The incidence of LN is variable among 
different ethnic groups suggesting that genetic factors play a role in its pathogenesis. 
Primarily, individuals of African ancestry are at increased risk for LN [4]. 
Immunosuppressive treatment is effective in only about 50% of LN patients, and that 





identifying the molecular mechanisms responsible for the pathogenesis of LN is 
necessary to define more specific diagnostic and therapeutic targets.  Such understanding 
may provide biomarkers of disease state which would enable treatment to be 
administered most effectively along with assessment of positive response to therapy such 
that the treatment can be modified or stopped in a timely manner to best manage adverse 
side effects.   
These markers also provide important pathogenic insight and tools for testing new 
or improved therapeutics.  Historically, SLE was diagnosed based solely on clinical 
features (i.e. rash, arthritis) and only recent times have seen the development of 
quantifiable diagnostic markers for laboratory confirmation of clinical findings by 
measurement of immune cell profiles and activity, identification of specific 
autoantibodies, and identification of changes in protein expression profiles in bodily fluid 
(i.e. urine, blood, cerebral spinal fluid) [9].  Traditional approaches to biomarker 
discovery allowed only limited numbers of identified proteins per sample which, 
unfortunately, required an initial selection bias on the part of the researcher.  Recent 
improvements in mass spectrometry based approaches to novel biomarker discovery have 
allowed a level of insight not previously possible through the identification of thousands 
of proteins from individual samples.  Mass spectrometry-based studies aimed at defining 
diagnostic markers for SLE complications by comparing protein expression in normal 
and diseased bodily fluids have used two basic approaches; 1) assessment of protein 
expression differences from stained 2D gels followed by MALDI-TOF/TOF 
identification of the proteins in differing spots or 2) direct assessment and comparison of 





LN diagnosis, however, is still incredibly complex and interactions of genetic risks, 
environmental factors, and molecular events that contribute to the development of LN are 
only beginning to be defined. 
Finally, novel discoveries involving the molecular mechanisms behind LN 
pathogenesis, in particular the early events surrounding the inflammatory cascade which 
takes place following antibody deposition within the glomerulus, have the potential to 
contribute to the understanding of other antibody-mediated glomerulonephropathies.  
While outcomes and long term histological changes may differ due to systemic or local 
differences in these conditions, many share the same acute initiating event involving 
glomerular antibody deposition, and thus novel therapies directed at inhibiting pathogenic 
changes in this earliest stage of disease may find utility across the GN 
spectrum[1,3,5,7,12,15].  For a more complete understanding of the events following 
antibody deposition within the glomerulus, we must first discuss the cellular anatomy of 
the kidney and the current physiological understanding of the cell types involved in the 
glomerular response to damage.  
 
 
1.2 – Renal Anatomy and the Cellular Pathogenesis of Glomerular Inflammation 
 
The functional unit of the kidney is the nephron (Figure 1).  The glomerular 
capillaries serve as a size- and charge-dependent filtration barrier and are contained 
within the Bowman’s capsule which also includes non-capillary volume (Bowman’s 






Figure 1 – The Nephron 
The nephron is the functional unit of the kidney.  The glomerular ball is held within the 
Bowman’s Capsule which drains into the proximal convoluted tubule, which begins the 
Loop of Henle, tasked with concentrating the urine before exit into the distal 
convoluted tubule and eventual draining into the collection duct which empties into the 
renal pelvis. 






exiting the Bowman’s space, the ultrafiltrate is concentrated and modified by cells lining 
the tubular walls.  The direction of flow is as follows: the proximal convoluted tubule  
descending limb of the loop of Henle  ascending limp of the loop of Henle  distal 
convoluted tubule  and finally the collecting duct which drains the concentrated urine 
into the renal pelvis.  Pathologies have been reported at almost every point in the nephron 
and possess a multitude of instigating factors and as well as promising therapeutics [16].  
However, the instigating factors in GN are almost invariably involving the glomerulus 
itself, which is where we now turn our focus. 
 Three cell types are predominant within the glomerulus: endothelial cells, 
mesangial cells, and podocytes.  Figure 2 illustrates the arrangement of glomerular tissue.  
Endothelial cells line the endothelial side of the glomerular capillaries.  Mesangial cells 
produce and maintain a significant portion of the extracellular matrix that supports the 
glomerulus.  And finally, the epithelial podocytes are situated outside of the glomerular 
capillaries and critically support the glomerular capillary basement membrane.  
Podocytes accomplish this feat through cellular projections called foot processes, which 
interdigitate tightly to wrap the basement membrane.  Small gaps between foot processes 
are called slit diaphragms and are very highly regulated by expression of membrane 
spanning proteins as well as intracellular structures and the actin cytoskeleton.  Figure 3 
diagrams this anatomy in a healthy glomerulus.  Figure 3a shows regularly spaced foot 
processes with well-defined slit diaphragms separating them.  Figure 3b describes a 
number of critical proteins involved in maintaining the slit diaphragm, namely nephrin 
and the underlying actin cytoskeleton itself.  In pathologic conditions involving antibody 






Figure 2 – Diagram of Glomerular Structures 
A – Bowman’s Capsule, B – Proximal convoluted tubule, C – Distal convoluted tubule, 
D – Juxtaglomerular apparatus, 1. Basement membrane (Basal lamina), 2. Bowman's 
capsule – parietal layer, 3. Bowman's capsule – visceral layer, 3a. Pedicels (Foot 
processes from podocytes), 3b. Podocyte, 4. Bowman's space (urinary space), 5a. 
Mesangium – Intraglomerular cell, 5b. Mesangium – Extraglomerular cell, 6. Granular 
cells (Juxtaglomerular cells), 7. Macula densa, 8. Myocytes (smooth muscle), 9. Afferent 
arteriole, 10. Glomerulus Capillaries, 11. Efferent arteriole 
Illustration by : Michał Komorniczak 









Figure 3 - The Podocyte Slit Diaphragm Structures 
The podocyte slit diaphragm is an intensely maintained glomerular structure which is 
formed by the gap between podocytes foot processes.   Loss of foot process structure is a 
common sign of glomerular pathology.  (a) TEM image of cross section of GBM with slit 
diaphragm highlighted within the box.  (b) Illustration of known slit diaphragm proteins.  
Of particular note in this figure is the association of f-actin of the podocyte cytoskeleton 
in the maintenance of the slit diaphragm. 
Maddalena Gigante, Matteo Piemontese, Loreto Gesualdo, Achille Iolascon, and Filippo Aucella, “Molecular and Genetic Basis of 
Inherited Nephrotic Syndrome,” International Journal of Nephrology, vol. 2011, Article ID 792195, 15 pages, 2011. 
doi:10.4061/2011/792195 










changes as outlined in Figure 4.  Regularly-spaced slit diaphragms on the epithelial side 
of the glomerulus are lost as foot processes efface, fuse, form pseudocysts, and 
potentially detach from the glomerular capillary completely [17].   
It has been shown that mesangial cells respond to immunoglobulin, complement 
and cytokines by producing various cytokines and chemokines, resulting in increased 
endothelial cell expression of adhesion molecules that recruit and activate leukocytes 
[15,18,19].   Podocytes, too, are important factors in the glomerular inflammatory 
response, although they are markedly understudied.  It is known that inflammatory injury 
leads to podocyte dysfunction, podocyte damage is a primary cause of proteinuria, and 
podocyte loss into the urine may be a better marker for glomerular injury than proteinuria 
[17,20,21].  Only a handful of published works have investigated the possibility of a 
direct role of podocytes in the induction of GN.  Hewins et al. reported that IL-18 is 
expressed by podocytes in biopsies from patients with ANCA-associated vasculitis [22].  
Kuravi et al. reported that TNF-α stimulated cultured podocytes to release IL-6, resulting 
in inhibition of leukocyte adhesion to vascular endothelial cells [23].  Yet, the response of 
podocytes to immunoglobulin and/or complement deposition and their contribution to the 
inflammatory response remain markedly understudied.  These studies suggest that 
podocytes may participate in providing the cytokines and chemokines that control 
glomerular inflammation and further understanding of how the podocyte interacts with 
the immune system as well as the local tissue may provide pathogenic clues to more 
effective treatment or earlier diagnosis of poorly responding patients.  
In contrast to the unknown role of podocytes, neutrophils have long been 






Figure 4 - Foot Process Pathologies Following Injury 
The podocyte foot process is structurally sensitive to damage, and many insults can result 
in loss of foot process structure.  Diseased glomeruli frequently exhibit foot process 
effacement, pseudocyst formation and bare areas of the GBM. 





focus primarily on the role of monocytes, B-cells, T-cells, and dendritic cells [23–29].  
Neutrophils can release both reactive oxygen species and proteases contained in 
neutrophil granules have been reported to be responsible for degradation of the 
glomerular basement membrane and subsequent proteinuria [25–27].  Direct podocyte 
injury by neutrophils has not previously been evaluated.  A recent report by Devi et al. 
showed that the glomerulus is a unique capillary bed that is constitutively patrolled by 
neutrophils which are retained within the glomerulus in the absence of proinflammatory 
stimulation [28].  Glomerular inflammation induced by deposition of anti-GBM 
antibodies increased the neutrophil retention time by 3- to 4-fold without increasing the 
number of neutrophils entering the glomerulus.  Retention of neutrophils within the 
glomerulus, even in cases without proinflammatory stimulation, provides the opportunity 
for intimate interaction with local cells.  Due to the prolonged retention of neutrophils in 
the glomerular capillaries, it is possible that small changes in localized expression of 
proinflammatory cytokines and chemokines may play a part in the induction of neutrophil 
activation in local tissues.  Until this point, little has been known regarding the cytokine 
milieu secreted by podocytes and thus their role in disease pathogenesis.  The work 
presented in this dissertation seeks to describe these unknown processes in renal 
pathophysiology.   
 
 






 The transcription factor nuclear factor-kappa B (NF-κB) regulates the expression 
of hundreds of genes that control cell proliferation and survival, the cellular stress 
response, innate immunity, and inflammation. Dysregulation of NF-κB activity is 
associated with many human diseases, especially those involving chronic inflammation, 
and recent studies suggest that NF-κB plays a role in the incidence and severity of GN as 
well [30–34].  In particular, both mesangial cells and podocytes demonstrate NF-κB  
activation and cytokine production in response to proinflammatory mediators [35–37].  
Immunohistochemistry (IHC)-based studies have shown enhanced glomerular and tubular 
expression of NF-κB, NF-κB regulatory proteins, and NF-κB target pro-inflammatory 
cytokines in renal biopsies from LN patients, compared with normal controls and patients 
with minimal change disease [33,34].  Another report found that pharmacological 
inhibition of NF-κB reduced the development of autoantibodies and renal impairment in 
SLE susceptible FcγRIIb-deficient mice [30].  Treatment of spontaneous SLE developing 
SWRxNZB mice with a flavonoid, Apigenin, inhibited NF-κB mediated events in T cells 
and suppressed serum IgG levels resulting in delayed appearance of nephritis [31].  This 
inhibition of NF-κB signaling protects against development of disease, at least in part, 
through reduced expression of cytokines that are transcriptional targets of NF-κB (TNF-
α, IL-1β, IL-8, MCP-1, etc.) [30,33,34,38].   
NF-κB is activated by a variety of immune, inflammatory, and stress stimuli 
through many cytokine and toll-like receptors (TLR) and regulated through a complex 
interplay of proteins (recently reviewed in [39]).  Figure 5 provides a general outline of 
the pathway.  In resting cells, NF-κB is sequestered in the cytoplasm in an inactive state 






Figure 5 - NF-κB Activation 
In the canonical NF-κB pathway, the transcription factor dimer is sequestered in the 
cytoplasm by IκB.  Phosphorylation and polyubiquitination of IκB results in its 
proteosomal degradation and translocation of NF-κB to the nucleus.  This is 
accomplished by an Inhibitor kappa Kinase (IKK) complex which includes an α, β, and γ 
subunit.  The γ subunit is called NEMO and is activated through linear or lysine-63 
linked polyubiquitination by numerous upstream factors in the Inflammatory Activation 
Complex (IAC).   





phosphorylated, polyubiquinated through Lys48 linkages, and then degraded by the 
proteasome.  This releases an active NF-κB complex to translocate to the nucleus and 
drive target gene expression.  In the canonical NF-κB pathway, phosphorylation of IκB is 
mediated by the IκB kinase (IKK) complex, which consist of α, β, and γ subunits [42]. 
IKKγ is the regulatory subunit also referred to as NF-κB essential modulator (NEMO).  
Activation of IKK is mediated by an IKK Activating Complex (IAC), a diverse group of 
signaling proteins which includes TRAFs, RIPs, TAKs and IRAKs, and is assembled 
through protein-protein interactions to linear and lysine 63-linked and linear 
polyubiquitin chains and interacts with the linking protein MyD88 in TLR-mediated 
pathways [43–46].  NEMO binding to head-to-tail linked linear polyubiquitin chains or 
the Linear Ubiquitin Assembly Complex (LUBAC) also activates the canonical NF-κB 
pathway [44,47,48].  Tight regulatory control is required for NF-κB signaling to prevent 
excessive production of many proinflammatory mediators.   
 
  
1.4 – ABIN1 as a Regulator of NF-κB Signaling 
 
The ubiquitin-binding protein, A20 binding inhibitor of NF-κB 1 (ABIN1), was 
first described in 1999 by Heyninck et al using a yeast two-hybrid screen and defined as a 
novel inhibitor of NF-κB and important A20 interacting partner [49].  She later described 
the structure and function of ABIN1, making note of the sequence homology of the 
ubiquitin bindings domains (UBD) of ABIN1 and NEMO [50].  Initial mouse models 





embryonic lethality due to excessive liver apoptosis [51].  This embryonic lethality could 
be resolved through co-knockdown of the TNF-α receptor 1 alongside ABIN1, 
highlighting the importance of ABIN1 inhibition in the regulation of TNF-α induced 
signaling pathways [52].  Our lab returned to the original work of Heyninck et al to 
examine the homology between NEMO and ABIN1 as it pertains to autoimmunity and 
found that polyubiquitin binding to lysine 63-linked and linear polyubiquitin chains (as 
well as lysine 48-linked to a lesser degree) is required to prevent spontaneous immune 
hyperactivation in mice [53].   
It is now clear that ABIN1 has important inhibitory roles for NF-κB signaling 
related to its ability to bind polyubiquitinated proteins and modulate their function [52–
55].  Figure 6 depicts ABIN1-mediated inhibition of a general NF-κB pathway.  ABIN1 
binds to lysine 63-linked and linear polyubiquitin chains and contains the same UBD as 
NEMO that facilitates binding to other regulatory proteins, such as TRAF2/6, RIP1, 
IRAK1 and others [47,52,53,56–58].  It is not clear how ABIN1 inhibits NF-κB activity, 
but two possible mechanisms have been proposed: the first is that ABIN1 binding 
competes with NEMO binding to proteins required for activation of IKK, and the second 
is that ABIN1 recruits A20 to the IKK regulatory complex where A20 disrupts the 
interactions needed for IKK activation by removing lysine 63-linked or linear 
polyubiquitin moieties from regulatory proteins [59,60].  A20 has also been reported to 
mediate proteasomal degradation of ubiquitin processing proteins that mediate IKK 
activation [61]. Asp (D) to Asn (N) mutation at residue 485 (mouse) or 472 (human) of 
the UBD renders ABIN1 incapable of binding polyubiquitin chains on NF-κB activators 






Figure 6 – ABIN1-mediated Inhibition of NF-κB Signaling 
ABIN1 can bind polyubiquitinated substrates through its ubiquitin-binding domain 
(UBD). IKKγ (NEMO) is activated through lysine-63 linked and linear 
polypolyubiquitin binding as are many factors in the IAC.  ABIN1 binding may recruit 
A20 which can remove ubiquitin moieties from target proteins to inhibit their 
downstream functions.  






reported that a knock-in mouse in which wild type ABIN1 was replaced by 
ABIN1[D485N] induced constitutive activation of NF-κB signaling leading to elevated 
cytokine production and development of a progressive SLE-like autoimmune disease 
[53].  Renal injury in these animals was not characterized in this report.   
 
 
1.5 – Discovering a Protective Role for ABIN1 in Glomerular Disease Pathogenesis 
 
As outlined above, glomerular disease progression is highly associated with NF-
κB activation and NF-κB expression in podocytes is also tied to potentially destructive 
phenotypes.  Podocyte injury is made more severe by loss of nephrin in the slit 
diaphragm, which itself is known to inhibit NF-κB signaling, and NF-κB signaling in 
general has been shown to increase during progression to end-stage renal disease [63,64].  
It has been reported that expression of NF-κB proteins in podocytes was positively 
correlated to the severity of podocyte injury and subsequent proteinuria [33]. Genome 
wide association studies of American, European and Chinese SLE patients identified 
polymorphisms in ABIN1 which increased risk for developing disease [65–69].  What we 
currently know about ABIN1 suggests that it may have a role in the pathogenesis of 
glomerular disease.  Therefore, we hypothesize that functional ABIN1 expressed in 
glomerular tissue, particularly in podocytes, is critical for maintenance of the glomerular 
microenvironment, control of local inflammation, and preservation of proper renal 
function.   





proper glomerular inflammatory homeostasis.  Novel mass spectrometry methods for 
characterization of ABIN1 phenotypic changes to podocytes will highlight the 
importance of proper NF-κB signaling regulation within podocytes.  By using ubiquitin 
binding deficient ABIN1 in vivo and in vitro, the importance of functional ABIN1 to 
glomerular function will be described.  Human polymorphisms in the ABIN1 locus will 
be defined as specific risk factors for development of glomerular disease.  Pathological 
studies of tissue and cultured podocytes will define the role of ABIN1 in podocyte 
function.  And a novel proinflammatory axis that exists between podocytes and 
neutrophils will be defined as a potential initiating step in the pathogenesis of antibody-
mediated GN.  Finally, an inhibitor of neutrophil degranulation will be described with 













MATERIALS AND METHODS 
 
 
2.1 – Overview 
 
 Experimental characterization of intricate biological function requires numerous 
methods and rigorous, well-controlled experimental design.  This presented a daunting 
challenge.  I designed in vivo, in vitro, and ex vivo experiments capable of parsing the 
complex interplay of the immune system with a target tissue with a wide possibility of 
potential mechanisms, if any mechanism did in fact exist, to explain my hypothesis.  My 
experimental design aimed to disprove my hypothesis and, failing that, shed light on the 
potential role of ABIN1 in the pathogenesis of glomerulonephritis.   
 
 
2.2 – Molecular Biology and Genetic Protocols 
 
Polymerase Chain Reaction – DNA amplification for cloning or analysis was performed 





AccuPrime PFX (Invitrogen) was the polymerase and standard PCR master mixes were 
used (Invitrogen).  Reaction parameters were according to the manufacturer’s 
specifications: 3 minutes at 95 °C, followed by 30 cycles of 94 °C for 30 seconds, 
annealing at 50 °C for 30 seconds, extension at 72 °C for 30 seconds, with a final 
extension at 72 °C for 3 minutes.   
  
Bacterial Transformation – One Shot TOP10 Chemically Competent E. coli (Invitrogen) 
were utilized for transformation of bacterial stocks.  Stocks of chemically competent cells 
were mixed with 200 μg plasmid DNA on ice for 30 minutes followed by a 30 second 
heat shock in a 42 °C water bath, then return to ice for 2 minutes.  SOC media was added 
to the cells and they were incubated at 37 °C for 1 hour.  Transformed bacteria were then 
transferred to LB agar plates containing either Ampicillin (100 μg/mL) or Kanamycin (50 
μg/mL) to match the resistance markers on the plasmid and incubated overnight at 37 °C.  
The following morning, single colonies were selected and grown in LB broth (Fisher 
Scientific) overnight at 37 °C with gentle agitation at 300 RPM.  After 16-18 hours, the 
bacteria were pelleted through centrifugation at 5000 x g for 10 minutes and plasmid 
isolated as described below. 
 
Plasmid Preparation – Plasmid preparation was accomplished using the Qiagen Mini 
Prep Kit or the Qiagen Maxi Prep Kit depending on the amount of plasmid needed 
(Qiagen, MD).  The mini kit was sufficient for purification from 2-5 mL LB broth at high 
turbidity.  The mega kit was sufficient for purification from up to 100 mL LB broth at 






Restriction Enzyme Digest – All restriction digests utilized in the course of this 
dissertation used enzymes from New England Biolabs which was also the source for all 
buffers and BSA (as required).  Restriction digests were held at a static temperature 
(typically 37 °C) in an EdvoCycler (EdvoTek) if in a 50 μL or smaller volume, or in a 
water bath calibrated to 37 °C (Fisher Scientific).   
 
Agarose Gel Electrophoresis – DNA amplicon, purified RNA or digested plasmid were 
run on 1% agarose gels to separate the DNA fragments by size using a 1kb Plus DNA 
Ladder (Invitrogen) or a 10kb Plus DNA Ladder (Invitrogen) as appropriate.  Agarose 
gels were produced fresh using 1g powdered agarose (BioRad) per 100 mL 1x TAE 
buffer (BioRad).  Standard gels comprised 50mL total volume and could be scaled up or 
down depending on specific needs of the sample.  One volume of glycerol-based (5% 
final concentration) DNA loading buffer was mixed 4 volumes of sample and current was 
applied at an appropriate level for an appropriate amount of time to achieve sufficient 
separation of the dye bands from the starting lane.  Visualization of the DNA bands was 
achieved using Ethidium Bromide (Shelton Scientific) and UV excitation and digital 
image capture on the ChemiDoc MP (BioRad).   
 
RNA Isolation –RNA was isolated from various tissues using the Aurum Total RNA Mini 
Kit (Qiagen).  Appropriate volumes of starting samples were lysed with the lysis buffer, 
mixed 1:1 with RNA-grade Ethanol (Sigma) and bound to Aurum Mini Columns 





DNase protocol degraded genomic DNA, the final wash was applied, and purified RNA 
was isolated in RNase-free water.  Quantification of RNA was achieved by readings in 
duplicate or triplicate on a NanoDrop 2000c spec (Thermo).  All protocols using 
interaction with RNA required RNase-free materials, including tips, tubes and reagents.  
Great care was taken to prevent introduction of exogenous RNases from the environment.  
Many RNA samples were checked for sample integrity using gel electrophoresis and 
ethidium bromide staining as described above to assess a 2:1 ratio of staining for 28S and 
18S bands, respectively, with properly sharp lines.  This could be done post hoc and 
samples of RNA were always saved until completion of the experiment in case questions 
arose about sample integrity.   
 
Reverse Transcription of cDNA – Purified RNA was reverse transcribed into cDNA using 
the iScript Reverse Transcription Supermix for RT-qPCR which employed a proprietary 
blend of oligo (dT) and random primers to provide unbiased representation of both 5’ and 
3’ regions of transcript (BioRad).  Optimal conditions allowed 1 μg of template RNA in 
16 μL RNA eluate, combined with 4 μL 5x Supermix, to allow a 20 μL reaction volume 
as required.  If RNA concentrations for the experiment were not sufficient in ALL 
samples to produce 1 μg template RNA in 16 μL reaction volume, all samples in the 
experiment were scaled down to a minimum input of 200 ng RNA per sample.  This 
range was determined to be optimal in our lab for our transcript targets using our 
equipment and is not intended discount the much wider ranges published by BioRad.  
The 20 μL final reaction volume could be scaled up to produce additional cDNA if 





thermocycler (BioRad) or an EdvoCycler Model 541 (EdvoTek).  Each sample was 
mixed on ice and cycling parameters were as follows: priming at 25 °C for 5 minutes, 
reverse transcription at 42 °C for 30 minutes, and enzyme inactivation at 85 °C for 5 
minutes, followed by a static hold at 4 °C.  cDNA was used immediately or stored at -20 
°C with limited freeze/thaws in this final RT solution using the protocol volumes 
described below.   
 
Primer Preparation – Primers for RT-qPCR were prepared using the database and 
software Primer-BLAST (NCBI) and selected custom primers were produced by 
Invitrogen (Carlsbad, CA).  PCR product size was optimized for the transcript but 
generally was limited to 70-300 bp based on cycling parameters and Tm was optimized 
for each transcript as well.  Multiple primer pairs were produced and tested for every 
transcript and for potential off target effects or primer dimers by melt-curve analysis on 
all analyzed samples.  Primers which spanned introns were preferred to reduce 
interference of contaminate genomic DNA.   
 
Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) – iTaq Universal SYBR 
Green Mastermix (BioRad) was used at 1x in a final reaction volume of 20 μL per well of 
a 96-well RT-qPCR plate (BioRad).  Each reaction included a final concentration of 0.4 
μM forward and 0.4 μM reverse primers optimized to be effective at that concentration 
for simplicity, and 1 μL of output cDNA from the reverse transcription protocol.  Only on 
rare instances were these parameters changed.  SYBR green was used for its low cost and 





melt curve analysis with each run.  Thermocycling was performed on a CFX96 (BioRad).  
Following a 2 minute activation at 95 °C, 40 cycles were completed of denaturation at 95 
°C for 15 seconds followed by annealing and extension at 60 °C for 40 seconds.  The 
melt curve analysis progressed from 65 °C to 95 °C in 0.5 °C steps with 5 seconds per 
step.  Housekeeping genes were optimized for each experiment but were typically either 
GAPDH or 18s rRNA, depending on stimulant and concentration of target.  Fold changes 
were calculated using the ΔΔCt method.   
 
Genome-Wide Association Study – A total of 16,999 independent case and control 
samples were collected from multiple sites as part of the Large Lupus Association Study 
2 (LLAS2) with the Institutional Review Board (IRB) approval from each institution and 
processed at the Oklahoma Medical Research Foundation (OMRF) under the auspices of 
the OMRF institutional review board. Only individuals who signed informed consent 
forms were included in the study. All SLE cases met the revised 1997 American College 
of Rheumatology for classification of SLE.  Among SLE cases, those with lupus nephritis 
fulfilled the renal criterion of either (1) persistent proteinuria >0.5 g per day (24 h) or 
persistent >3+ if quantification was not performed or (2) presence of urinary cellular 
casts (Table 2). All SLE cases met the revised 1997 American College of Rheumatology 
for classification of SLE [70].  Among SLE cases, those with lupus nephritis fulfilled the 
renal criterion of either (1) persistent proteinuria >0.5 g per day (24 h) or persistent >3+ if 
quantification was not performed or (2) presence of urinary cellular casts [70].  The 
custom-design Illumina iSelect platform at OMRF was used to genotype 5 SNPs in 





rs3792783, rs2233287) [71], SLE (rs7708392) [67], psoriasis (rs3762999, rs999556, 
rs17728338) [72,73], and psoriatic arthritis (rs17728338, one of psoriasis SNPs) [74].  In 
addition, 347 ancestral-informative markers (AIMs) spanning the genome were 
genotyped.  After application of quality controls by excluding samples if they exhibited 
low call rates (<90%) and extreme heterozygosity (>5 standard deviations from the 
mean), revealed discrepancies between reported gender and genetic data, or were 
determined to be a duplicate or cryptic related to another sample (the proportion of alleles 
shared identical by descent >0.4), and removing extreme population outliers based on 
global ancestry estimation and principal component analysis (calculated using the AIMs 
in the ADMIXMAP[75,76] and EIGENSTRAT[77] programs, respectively) as described 
in other LLAS2 reports [66,78], a final dataset of 15,864 unrelated subjects was obtained.    
Single marker association analyses were calculated using the logistic regression function 
in PLINK v1.07 [79].  The additive genetic model was applied while adjusting for gender 
and global ancestry estimates (African, European, and East Asian) [66,80,81].  The 




2.3 – Plasmids and Lentiviral Transduction 
 
pCMV6-AC-mGFP – This cloning system was purchased from Origene to produce GFP-
tagged ABIN1 in cultured cells at a higher level than endogenous ABIN1 was produced.  





used.  This plasmid also conferred ampicillin resistance for selection and high level 
production in bacterial cultures.  An insert sequence was produced and sent to Origene 
for production.  Plasmid sequences were confirmed before being used and both GFP and 
ABIN1 proteins were recognized appropriately by all methods employed in the course of 
this study. 
 
pCMV6-AC-DDK – This cloning system was produced as the GFP tagged system above, 
but rather than GFP, it included a DDK tail (non-proprietary FLAG system) for protein 
purification.   
 
Lentiviral Transduction using MDM00734 pCSC-SP-PW – Some cells are resistant to 
transient transfection due to sensitivity to transfective agents or other reasons, thus 
Lentiviral transduction was used as an alternative, which produces stable expression of 
target proteins in difficult to transfect cells.  This plasmid was designed by Michael 
Mendenhall of the University of Kentucky Viral Core.  With the help of Dr. Mendenhall, 
we designed a protocol for isolating ABIN1 inserts of the appropriate genotype (WT and 
ABIN1[D472N] and others) from transfection plasmids and production of lentivirus 
capable of transduction of cultured podocytes.  Per the University of Louisville IRB 
Approval, no virus was reproduced in University of Louisville facilities.  All local viral 
stocks were replication deficient.  An optimized multiplicity of infection (MOI) of 1-10 
based on viral titer was used for each cell type and optimized to achieve equal expression 
of WT, ABIN1[D472N] or other genotype.  Lentiviral stocks were aliquoted, frozen for 





(TTP) in 2 mL appropriate cell culture media were exposed to an appropriate volume of 
lentivirus in polybrene at 8 μg/mL (a kind gift of Dr. Mendenhall).  Following an 8 hour 
incubation, media was removed and a second volume of 2 mL media with virus and 8 
μg/mL polybrene was added and allowed to infect overnight.  Fresh media was applied 
and cells were allowed to grow for 72 hours before transduction could be checked via 
fluorescence microscopy on an inverted CKX41 (Olympus).  Expression was confirmed 
via RT-qPCR, sequencing, western blot and other methods.   
 
 
2.4 – Antibodies 
 
ABIN1 – For detection of ABIN1, a mouse monoclonal antibody (Santa Cruz – sc-
376999) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight 
at 4 degrees followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at 1:2000 (200 
μg/mL stock) for 1 hour at room temperature and chemiluminescent using Clarity 
Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and 
ImageLab 3.0 Software (Biorad). 
 
MCP-1/CCL2 – For detection of MCP-1, a mouse monoclonal antibody (Santa Cruz – sc-
377082) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight 
at 4 degrees followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at 1:2000 (200 





Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and 
ImageLab 3.0 Software (Biorad). 
 
GAPDH – For detection of GAPDH, a rabbit polyclonal antibody (Santa Cruz – sc-
25778) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight 
at 4 degrees followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200 
μg/mL stock) for 1 hour at room temperature and chemiluminescent using Clarity 
Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and 
ImageLab 3.0 Software (Biorad). 
 
ET-1 – For detection of Endothelin 1, a goat polyclonal antibody (Santa Cruz – sc-21625) 
was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 
degrees followed by rabbit-anti-goat -HRP (Santa Cruz – sc-2768) at 1:2000 (200 μg/mL 
stock) for 1 hour at room temperature and chemiluminescent using Clarity Western ECL 
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0 
Software (Biorad). 
 
ERK 1 – For detection of ERK 1, a rabbit polyclonal antibody (Santa Cruz – sc-94) was 
used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 degrees 
followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200 μg/mL stock) 
for 1 hour at room temperature and chemiluminescent using Clarity Western ECL 






IκBα  – For detection of IκBα, a rabbit polyclonal antibody (Santa Cruz – sc-847) was 
used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 degrees 
followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200 μg/mL stock) 
for 1 hour at room temperature and chemiluminescent using Clarity Western ECL 
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0 
Software (Biorad). 
 
p-IκBα – For detection of phosphorylated-IκBα, a rabbit polyclonal antibody (Santa Cruz 
– sc-101713) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS 
overnight at 4 degrees followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 
1:2000 (200 μg/mL stock) for 1 hour at room temperature and chemiluminescent using 
Clarity Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station 
and ImageLab 3.0 Software (Biorad). 
 
Podocin – For detection of podocin, a rabbit polyclonal antibody (Santa Cruz – sc-21009) 
was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 
degrees followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200 μg/mL 
stock) for 1 hour at room temperature and chemiluminescent using Clarity Western ECL 
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0 
Software (Biorad). 
 
p-ERK – For detection of phosphorylated ERK, a mouse monoclonal antibody (Santa 





overnight at 4 degrees followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at 
1:2000 (200 μg/mL stock) for 1 hour at room temperature and chemiluminescent using 
Clarity Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station 
and ImageLab 3.0 Software (Biorad). 
 
A20 – For detection of A20, a mouse monoclonal antibody (Santa Cruz – sc-376564) was 
used at 1:100 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 degrees 
followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at 1:2000 (200 μg/mL stock) 
for 1 hour at room temperature and chemiluminescent using Clarity Western ECL 
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0 
Software (Biorad). 
 
β-actin – For detection of β-actin for use as a loading control, a mouse monoclonal 
antibody conjugated to HRP (Santa Cruz – sc-47778-HRP) was used at 1:500 dilution 
(200 μg/mL stock) in 5% milk in 1x TTBS for 1 hour at room temperature and 
chemiluminescent using Clarity Western ECL Substrate (BioRad) on the BioRad 
ChemiDoc MP Image Station and ImageLab 3.0 Software (Biorad). 
 
 
2.5 – Cell Culture 
 
Conditionally Immortalized Podocytes – In 2002, Moin Saleem published his 





sensitive SV40-T-gene that revolutionized almost all modern research into podocyte 
biology [82].  Briefly, these cells grow permissively at 33 °C, but upon exposure to 37 °C 
temperatures for 7-10 days, they enter growth arrest and express markers of differentiated 
podocytes in vivo.  These cells were grown in RPMI-1640 without glutamine 
(Invitrogen), supplemented with 1x Pen/Strep/Glutamine (Invitrogen), 10% fetal bovine 
serum (Sigma), and 1x Insulin/Transferrin/Selenium-X (Invitrogen).  Many stimulants 
were used, but this dissertation focuses on TNF-α (100ng/mL) (BioLegend) for all cell 
culture work.    
 
Podocyte Actin Labeling and Confocal Microscopy – Confocal microscopy images were 
obtained as previously described[83].  Briefly, 35mm collagen-coated glass bottom 
dishes (MatTek) were seeded with podocytes and allowed to mature at 37 °C for 10 days.  
Cells were serum starved with 0.5% FBS medium 24 h before stimulant was added.  
Following stimulation, cells were rinsed three times with PBS that contained calcium and 
magnesium and fixed in 3.7% paraformaldehyde (Azer Scientific) in PBS (Invitrogen) for 
10 min, followed by permeabilization with 0.025% NP-40 (Sigma) in PBS for 15 min and 
washing.  Cells were blocked in 5% BSA (Sigma) in PBS for 30 minutes before addition 
of 200 μL (3 units) rhodamine-phalloidin (Thermo) for 30 minutes.  Following another 
wash, 300 nM DAPI (Invitrogen) was incubated for 5 min, and rinsed three times with 
PBS, mounted using Vectashield Antifade Mounting Medium for Fluorescence (Vector 
Labs). Images were acquired using a Zeiss confocal microscope and analyzed using 
LSM510 software. The images for rhodamine were analyzed by FibrilTool as 







2.6 – General Protein Expression Assays 
 
Sample Preparation and Cellular Lysis – Cultured cells were washed 3 times with ice-
cold PBS and lysed in RIPA Buffer (Sigma) containing 1x Protease Inhibitor Cocktail 
(Sigma) and 1x Phosphatase Inhibitor Cocktail (Santa Cruz).  Lysis was allowed to 
proceed on ice for 30 minutes followed by a centrifugation at 20,000 x g for 30 minutes 
at 4 °C to pellet cellular debris.  An appropriate volume of lysis buffer was used to 
accommodate either the confluency of cells on the plate or the approximate size of the 
cell pellet. 
 
Protein Quantification – Protein concentration was estimated using the BCA method 
(Thermo) in triplicate according to the manufacturer’s protocol.  Lysis buffer or vehicle 
into which the sample is diluted was used as a blank and serial dilutions of BCA 
(Thermo) were used to generate a standard curve. 
 
SDS-PAGE – Appropriate volumes of protein sample and water were added to 5x 
Laemmli Sample Buffer (final concentration 60 mM Tris-Cl pH 6.8, 2% SDS, 10% 
glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue) to achieve equal estimated 
loading of all samples to be loaded in the gel.  Mini-PROTEAN TGX pre-cast 4-20% 
gradient gels (BioRad) were immersed in 1x Tris-Glycine-SDS buffer (BioRad) and run 





size of target proteins.  Precision Plus Dual Color protein standard (BioRad) was used to 
gauge size of bands identified in western blot protocol (in kDa). 
 
Polyvinylidene Fluoride (PVDF) Transfer – PVDF (BioRad) was used rather than 
nitrocellulose.  PVDF was rehydrated for at least one minute in 100% methanol (Sigma) 
followed by at least 10 minutes in 1x Tris-Glycine transfer buffer (BioRad).  Semi-dry 
transfer was achieved using the Trans-Blot Turbo (BioRad) at appropriate current 
(usually 300 mA but varied based on sample).  Totality of transfer was assessed by 
staining the gel post-transfer with Coomassie stain for 15 minutes followed by 1-4 hours 
of destain in 40% methanol (Sigma) and 10% acetic acid (Sigma).    
 
Western Blotting – PVDF membrane was washed 3 times in 1x TTBS followed by >30 
minute block in 5% milk (Great Value) in TTBS.  Appripriate dilutions of primary and 
secondary antibodies were added to 5% milk in TTBS.  Primary antibodies were allowed 
to bind overnight at 4 °C with rocking, followed by 3 washes in 1x TTBS.  HRP-
conjugated secondary antibodies were allowed to bind for 1 hour at room temperature 
with gentle rocking before washing 3 times in 1x TTBS.  Chemiluminescent detection 
was achieved using Clarity Western ECL Substrate (BioRad) on the BioRad ChemiDoc 
MP Image Station and ImageLab 3.0 Software (Biorad). 
 
Enzyme-Linked Immunosorbent Assay (ELISA) – Secreted cytokine levels for MCP-1, IL-
8, and TNF-α were analyzed using the BioLegend ELISA Max Deluxe kits per the 





neutrophils, samples were stimulated for 6 hours with TNF-α followed by 3 washes in 
sterile, endotoxin-free Krebs buffer, followed by a 6 hour collection in 10mL Krebs 
buffer per 10cm dish at 70% confluence.  This stimulation and wash regimen was 
determined to be optimal for the cytokines of interest and no detectable TNF-α remained 
following the 3 wash steps (<<2pg/mL). 
 
Luminex-based Cytokine Arrays – Blood was collected from mice by cardiac puncture, 
allowed to clot, and the serum was separated by centrifugation.  Cytokines in mouse 
serum were measured using the Bio-Plex Mouse Cytokine 23-plex assay on the Bio-Plex 
MAGPIX Multiplex reader according to the manufacturer’s protocol (Bio-Rad). 
 
 
2.7 – Mass Spectrometry Based Protein Detection 
 
Label-free Sequencing and Quantification of Total Protein – Briefly, protein 
concentration was estimated using the BCA method (Thermo, Rockford, IL), diluted with 
6M urea in 100 mM ammonium bicarbonate, reduced with dithiothreitol and alkylated 
with iodoacetamide. The sample was digested using sequence-grade trypsin at a 1:100 
ratio of trypsin to sample protein and incubated overnight at 37 °C with shaking, then 
desalted and concentrated using a fused silica microcapillary C-18 column (Michrom 
Bioresources, Auburn, CA). The resulting peptides were analyzed by a Thermo Fisher 
Scientific LTQ-Orbitrap Elite mass spectrometer coupled with a Proxeon Easy nanoLC 





Sequest Sorcerer (Sage-N Research, San Jose, CA), set up to search a FASTA formatted 
human protein database (Human RefSeq). High-probability peptide and protein 
assignments were made using Peptide and Protein Prophet algorithms[85]. Abundance of 
each identified protein was determined by normalizing the number of unique spectral 
counts matching to the protein by its predicted molecular weight, termed the protein 
abundance factor [5,86,87].  Cytokine production by unstimulated ABIN1 WT-
expressing podocytes was defined as the normal cytokine secretome and was compared to 
the ABIN1 WT stimulated and both stimulated and non-stimulated ABIN1[D472N] 
dataset to identify changes to the normal secretome of these cells. 
 
Secretome Identification, Size Selective – Most cytokines are small proteins and we have 
found that sample purity is increased through a 10 minute centrifugation in an Amicon 
Ultra-30kDa Centrifugal Filter Unit (Millipore, Billerica, MA) to remove proteins larger 
than 30 kDa, followed by preparation as we have previously described.  
 
 
2.8 – Animal Handling and Assays for Primary Tissue  
 
Transgenic Mice – The ABIN1[D485N] global knockin mice were generated on a 
129SvJxC57BL/6 background[53] and then backcrossed eight generations to C57BL/6 
for the present studies.  Heterozygous mice were used to generate ABIN1[D485N] 
homozygous and littermate WT control mice for all the experiments.  Female mice from 





pathogen free conditions and all studies were approved by the Institutional Animal Care 
and Use Committee of the University of Louisville (Louisville, KY).   
 
Bone Marrow Transplant and Development of Chimeric Animals – Bone marrow 
transplant was carried out as previously described[88].  Briefly, 5-7 week old female 
mice were conditioned with 950 cGy total body irradiation from a caesium source 
(Gamma-cell 40; Nordion, Ontario, Canada). At 24 h post irradiation, the mice were 
transplanted with bone marrow cells (1 x 107 cells per mouse in 0.1 ml PBS) isolated 
from tibias and femurs of age-matched donor mice, through the retro-orbital plexus with 
a 27-gauge needle. Ten WT mice received WT bone marrow and ten received 
ABIN1[D485N] bone marrow.  Likewise, ten ABIN1[D485N] mice received WT bone 
marrow and ten received ABIN1[D485N] bone marrow.  Engraftment was allowed to 
proceed for 5-7 weeks before administration of α-GBM. Engraftment was confirmed 
using leukocytes isolated from whole blood.  Both the recipient and donor mice were 
maintained on normal chow throughout the experiment.   
 
Urine Albumin:Creatinine Measurements – Spot urine samples were captured by 
scruffing the mice and massaging the bladder over a clean, disposable surface and 
collected in a sterile microcentrifuge tube. Urine was centrifuged at 5000 x g for 5 
minutes then standard sandwich ELISA was performed in triplicate according to the 
manufacturer’s protocol for mouse albumin (Bethyl) and a kinetic Jaffe method for 
creatinine (Thermo).  The ratio of albumin (μg/mL) and creatinine (mg/mL) was 






Serum C3 Quantification – Serum was collected from ABIN1[D485N] and WT mice at 
ages 3-4 months and 5-6 months. C3 measurements were performed using a 1:25,000 
dilution of mouse serum and measurement with the Mouse C3 ELISA Kit from GenWay 
Biotech (#40-374-130047) per the manufacturer’s guidelines. All samples were tested in 
duplicate and the average was reported.  
 
Histopathology and immunohistochemical staining of mouse cortical tissue – Formalin-
fixed, paraffin embedded tissues were stained with PAS reagent for histological analysis 
by light microscopy.  Glomerular damage was assessed by semiquantitative scoring of 
cellularity and mesangial matrix expansion on a 0 (normal), 1+ (mild abnormality), 2+ 
(moderate abnormality), and 3+ (severe abnormality) scale. For immunohistochemical 
labeling of proteins, sections were deparaffinized in xylene and rehydrated in graded 
alcohols.  Antigen retrieval was achieved using citrate buffer solution for 20 minutes at 
95 °C (Dako), slides were washed in buffer and endogenous peroxidases were quenched 
with H2O2 for 5 minutes before washing and a 30 minute block in buffer containing 5% 
BSA and 2% sera at RT.  Primary antibody was applied overnight at 4 °C and 1:200 
dilution for WT-1 (Santa Cruz), CD45 (Angio-Proteomie), 1:50 dilution for MPO 
(AbCam) or with buffer only as a negative control followed by washing and incubation 
with appropriate secondaries at 1:200 dilution.  All sections including negative controls 
were then incubated with respective biotinylated secondary antibodies (1:200, Vector 
Labs), followed by incubation in avidin/biotinylated enzyme complex (Vectastain Elite 





diaminobenzidine (DAB) as substrate (Vector Labs). Counterstaining was performing 
using hematoxylin (Vector Labs) and cells were dehydrated, mounted and viewed at 
100x.  Digital Images were obtained with a Q Color 5 camera attached to an Olympus 
BX51 microscope using Image-Pro software. 
 
Immunofluorescence – For immunofluorescent analysis of C3, IgA or IgM, 4 micron 
frozen sections were first washed in PBS 3x5 minutes each. The blocking solution was 
applied for 30 minutes at room temperature. The primary antibody was then added for 2 
hours at room temperature. The sections were washed for 5 minutes in PBS three times. 
FITC primary antibody (C3- Cedar Lanes Laboratory, IgG- Sigma Aldrich, C1q- Hycult 
Biotech) or unlabeled primary antibody (IgA-Invitrogen, IgM-Invitrogen) followed by 
florescent secondary antibody (Alexa Flour 555- Invitrogen) were used. Following 
antibody incubation, slides were washed in PBS 3x5 minutes.  Images were acquired 
using a Zeiss confocal microscope and analyzed with LSM510 software. 
 
Transmission Electron Miscroscopy – Freshly dissected cortical tissue was placed in a 
cryomold with OCT compound (Tissue-Tek) and flash frozen in liquid nitrogen. Thick 
(1-mm) sections were prepared to evaluate the orientation and presence of glomeruli. 
Thin sections were mounted on 200 mesh naked copper grids and stained with lead citrate 
and uranyl acetate (4% in absolute alcohol). Sections were prepared for electron 
microscopy by postfixing in osmium, dehydrating in an alcohol series, and embedding in 
Durcupan resin (Ted Pella, Redding, CA) and imaging via a CM10 transmission electron 






Therapeutic Caffeination of Researcher – To achieve sufficient levels of cognition to 
conform to University of Louisville Occupational Health and Safety guidelines, daily 
consumption of 3-5 aliquots of 8.5g prepared dark blend or similar ground coffee bean 
(Caza Trail or similar) was performed on a B70 Platinum Brewing System (Keurig) 
followed by supplementation with 72 mg saccharine (Cumberland Packing Corporation).  
Physiological changes were monitored and dosing modified as necessary.   
 
Glomerular purification – To obtain 95% pure glomeruli for RNA extraction, we utilized 
a common sieving technique in small batches.  Briefly, renal cortex is dissected and 
minced followed by collagenase treatment (Sigma), initial filtration through 100nm nylon 
mesh (VWR) and glomerular purification and washing with Hanks Buffer (Invitrogen) in 
a 70nm nylon mesh (VWR).  Glomerular samples obtained were determined to be at least 
90% glomeruli by light microscopy with <5% tubule contamination.   
 
Purification of Primary Neutrophils from Donor Blood – The Percoll method is a 
standard density gradient capable of separating cellular components of whole blood.  
Briefly, whole blood from donors was centrifuged at 500 x g for 35 minutes at 25 °C, 
with neutrophils forming a distinct band which can be purified.  Isolated neutrophils were 
diluted in endotoxin-free, sterile Krebs buffer.  Microscopic evaluation of isolated cells 
showed that >92% of cells were neutrophils.  Trypan blue exclusion indicated that >95% 
of cells were viable.  The Institutional Review Board of the University of Louisville 






Stimulation of Primary Neutrophils and Isolation of Granule Contents – Neutrophil 
granule contents were produced by stimulating donor neutrophils with TNF-α (2 ng/mL) 
(Sigma) and 300 nM N-Formyl-Met-Leu-Phe (fMLF) (Sigma) for 30 minutes at 37 °C in 
Krebs buffer.  Neutrophil cell bodies were removed via centrifugation for 5 minutes at 
5000 x g.   
 
Neutrophil Chemotaxis – Donor neutrophils were resuspended at 5 x 104 in Krebs buffer 
and 100 μL of suspended PMNs were allowed to undergo chemotaxis per manufacturer 
guidelines into 6.6mm diameter and 3μM pore size Transwell Permeable Supports 
(Corning) using a 1:600 dilution of cell culture supernatant in sterile, endotoxin-free 
Krebs buffer.  The Hema 3 protocol (Fisher) was used to fix and stain the membranes.   
 
Neutrophil Degranulation – Degranulation of specific and azurophilic granules was 
determined by measuring binding of FITC-conjugated monoclonal anti-CD35 
(Pharmingen) and FITC-conjugated monoclonal anti-CD66b (Accurate Chemical) on 4 × 
106/ml neutrophils using a FACSCalibur flow cytometer (Becton Dickinson, Franklin 
Lakes, N.J., USA) as previously described[89]. 
 
Nephrotoxic Sera and TAT-SNAP23 Administration – Nephrotoxic sera (a kind gift of Dr. 
David Salant) or control sera (Rockland) was injected into the tail vein of mice at 
1.5mg/25g mouse body weight.  TAT-SNAP23 was produced by Dr. Kenneth McLeish.  





competent cells (Invitrogen).  E. coli BL21-AI cells (Invitrogen) were used to 
overexpress the recombinant TAT fusion proteins which were purified by Ni-NTA beads 
(Invitrogen). Administration of TAT-SNAP23 was via tail vein injection at the time of α-
GBM administration and 6 hours after administration at a concentration of 0.05mg/kg 













PROTEOMIC APPLICATIONS FOR DEFINING CELLULAR MECHANISMS AND 
DIAGNOSTIC MARKERS OF SYSTEMIC LUPUS ERYTHEMATOSUS 
 
 
3.1 – Overview of mass spectrometry and discovery proteomics 
 
As described in the Introduction, autoimmune diseases such as systemic lupus 
erythematosus (SLE) can affect many different body systems, including the central 
nervous system, blood cells, joints, skin, heart, lungs, and kidneys [11]. The molecular 
mediators which promote disease pathogenesis are not fully known, thus a primary 
objective of translational research is the identification of reliable, non-invasive, and 
quantifiable markers for detection of the early-onset of specific complications.  Such 
markers would enable treatment to be administered most effectively along with 
assessment of positive response to therapy such that the treatment can be modified or 
stopped in a timely manner to best manage adverse side effects.  These markers also 
provide important pathogenic insight and tools for testing new or improved therapeutics.  
In addition to clinical features (i.e. rash, arthritis), diagnostic information for SLE or GN 





specific autoantibodies, and identification of changes in protein expression profiles in 
bodily fluid (i.e. blood, cerebral spinal fluid, lavage fluid, and importantly in GN, urine).   
Mass spectrometry-based proteomic technologies have played an important role 
in each area of clinical diagnosis as well as the development of a more comprehensive 
understanding of the underlying disease process using a myriad of diverse sample types 
and techniques.  One of the preferred mass spectrometry methods in proteomics 
combines one or two dimensional (1D or 2D) liquid chromatography (LC) peptide 
separation with electro-spray ionization (ESI) tandem mass spectrometry (MS/MS) [90]. 
This LC-MS/MS methodology allows for a direct and highly-sensitive identification of 
hundreds of individual proteins from virtually any type of biomedical sample [91].  The 
decision to use 1D versus 2D-LC is based on the complexity of the protein sample.  
Typically SDS-PAGE bands or spots (< 30 proteins) are analyzed by 1D and much more 
complex samples, such as affinity-purifications and whole cell, tissue, or bodily fluid 
extracts are analyzed with 2D-LC-MS/MS.  Another type of mass spectrometry that is 
employed is matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) 
[92].  With this approach up to 96 individual protein samples are spotted onto a stationary 
target for analysis. Although the sensitivity of MALDI-TOF is limited to characterizing 
the 10-15 most abundant proteins in each sample, it has the benefit of being a higher 
throughput platform for lower complexity, pre-fractionated protein mixtures (i.e. gel 
separation) because each sample is analyzed in minutes where as a typical 1D-LC run 
requires an hour and 2D-LC-MS/MS takes 10-12 hours.  A third mass spectrometry 
approach is surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF), a 





such as strong anion exchangers or hydrophobic characteristics, allow binding of proteins 
with certain characteristics while dissimilar proteins are washed away. This allows 
analysis of targeted subsets of structurally related proteins and reducing the complexity of 
the sample improves the overall sensitivity or dynamic range of detection.  SELDI-TOF 
results differ from LC-MS/MS and MALDI-TOF/TOF in that the results are given in 
mass to charge ratios (m/z) rather than peptide sequence, so positive protein identification 
is not possible.  It is, however, useful for rapid analysis of the protein m/z profiles of 
semi-complex samples by reducing upfront separation while preserving the fast analysis 
time of a MALDI platform.  Although not as desirable for discovery, these attributes of 
relative ease of sample preparation and speed of analysis and data output, as well as 
lower startup and operation costs presents SELDI-TOF as a more suitable mass 
spectrometry platform for a clinical test.         
A key component of these studies is the method used to prepare selectively 
targeted protein samples for mass spectrometry interpretation.  Auto-antigen 
identification studies usually involve separation of the tissue of interest by 1D or 2D 
electrophoresis (1-DE or 2-DE) SDS-PAGE, followed by immuno-blotting with anti-sera 
from SLE patients, and identification of proteins in immune-reactive bands by MALDI-
TOF/TOF or LC-MS/MS analysis [94].  Another approach isolates autoantibodies from 
SLE patient serum using immobilized protein G which is then used to affinity enrich 
antigens in targeted tissue extracts for direct characterization with 2D-LC-MS/MS 
analysis [95].  As mentioned above, studies comparing diseased and healthy body fluids 
use two general approaches; 1) 2D gel electrophoresis followed by staining of total 





comparison of total protein expression using LC-MS/MS [94,96].  The work flow of 
these applications is described in Figure 7.  Starting from sample, which could be any 
preparation of proteins, work flow could lead to a number of separation/purification 
techniques or proceed directly to tryptic digestion.  Both 1-DE and 2-DE are used to 
immunoblot for novel autoantigens followed by analysis, frequently MALDI or SELDI, 
but also including 1D and 2D-LC-MS/MS.  Complex samples may be separated by 
affinity chromatography, immunoprecipitation or magnetic bead separation.  Techniques 
may be employed to remove primarily high-abundance proteins, separate based on 
protein chemistry or interaction kinetics involving immunoglobulins or other proteins.  
The digested peptides could be subjected to analysis by MALDI, SELDI, and 1D- or 2D-
ESI-LC/MS/MS.  Gel separated and digested proteins are frequently analyzed with 
MALDI or SELDI platforms, but are appropriate for ESI as well.  More complex sample 
types, in particular whole cell lysates, which have not been separated, are frequently 
subjected to 1D- or 2D-LC peptide separation coupled with ESI-MS/MS analysis.  The 2-
dimentional aspect of LC separation allows a greater number of proteins to be identified 
from very complex samples when compared to the other methods, with the tradeoff being 
the greatly increased time (10-12 hours) to analyze one sample. SELDI-TOF and 
MALDI-TOF are used for profiling while MALDI-TOF-TOF and ESI-MS/MS can 
sequence the peptides in the sample to positively identify their parent proteins.   
Finally, we provide a mechanism by which LC-MS/MS was used to define the 
proteome of cell culture supernatant which is later assessed for its ability to activate 






Figure 7 - Flowchart of LC-MS/MS Sample Preparation 
Abbreviations: 1-DE, One-Dimensional Electrophoresis; 2-DE, 2-Dimentional 
Electrophoresis; SELDI, Surface-Enhanced Laser Desorption/Ionization; MALDI, 
Matrix-assisted laser desorption/ionization; 1D-LC, One-Dimensional Liquid 
Chromatography; 2D-LC, Two-Dimensional Liquid Chromatography; TOF, Time-of-
Flight; ESI, Electrospray Ionization 
 





Here I seek to explain prior contributions of mass spectrometry techniques to the 
biological understanding, diagnosis and treatment of SLE, in particular LN, and to lay out 
a framework for subsequent study of SLE, LN and GN.  It is the hope of any investigator 
that they can catalyze the dissemination of information to allow a greater understanding 
of complex techniques and illustrate their potential in translational and clinical research 
related to human diseases.  Here I outline relevant contributions of LC-MS/MS and 
discovery proteomics and adapt protocols which will be utilized to study glomerular 
disease as described in Chapters IV and V.   
 
3.2 – Cardiovascular systemic lupus erythematosus 
 
 Systemic lupus erythematosus (SLE) is an autoimmune condition known to 
increase a patient’s risk for cardiovascular disease (CVD). Even when correcting for 
potentially confounding factors such as age, genetic background, treatment methodology, 
family history, disease profile, etc., SLE patients have been shown to have risk up to 50 
times above that predicted by Framingham Risk Factors [97–100]. While mortality rates 
for active disease have fallen in recent decades, mortality rates for CVD in long-term 
SLE patients continue to rise [97,100]. LN occurs in about 50% of SLE patients and is a 
major cause of morbidity and mortality, with a significant component attributed to  
increased risk of ischemic heart disease [10,101,102]. The genetic risks, environmental 
factors, and molecular events that determine susceptibility for LN are unknown. A great 
deal of effort has been put into understanding the changes to the cardiovascular system in 





but on average only 9% will develop true myocarditis [104,105].  SLE has long been 
known to result in immune deposits in the pericardium and/or myocardium of SLE 
patients, resulting in both histopathologic and gross anatomic changes [106].  
Arrhythmias including sinus tachycardia, atrial fibrillation, long QT, atrioventricular 
block and bundle branch block are rare complications, but can have significant effects 
when combined with other factors such as antimalarial therapy [105] and studies have 
reported up to 16% of children with SLE to have asymptomatic cardiovascular disease 
[107].  The risk of developing coronary artery disease is 4-8 times higher in SLE patients 
than in controls, and this risk increases to 50-fold in young women [98].  Treatment can 
be tailored to specific patients at risk for the development of such complications, but for 
this to be possible, early diagnosis of SLE is required followed by the accurate gauging of 
cardiovascular risk.  Mass spectrometry findings have been used to characterize the 
proteomic changes in the SLE disease state to better understand the pathogenic 
mechanisms behind cardiovascular disease to allow earlier diagnosis and improved risk 
assessment [96,108–111].  Relevant results are summarized in Table 1. 
To better understand pathogenesis of cardiovascular SLE and provide biomarkers 
for prompt diagnosis, autoantigens involved in congenital heart block were subjected to 
proteolytic cleavage with and without sera of SLE patients, followed by MALDI-TOF-
TOF identification of antibody-protected sites (epitopes) [110].  The resulting peptides 
were found to correspond to the 200-239 amino acid portion of the Ro52 protein, 
supporting the use of autoantibodies against Ro52 as a biomarker.  Subsequent studies 





Table 1 – Contributions of Mass Spectrometry to Cardiovascular Biomarker 
Discovery in SLE 







• Higher plasma Hpα2 seen in SLE vs. 
controls 
• Supporting research has implicated Hpα2 





• Antibody protected sites found with SLE 
sera in 200-239 amino acid portion of the 
Ro52 protein 
Both 
Annexin A6  [96] LC-MS/MS • Autoantibodies identified against Annexin 
A6 
• Activation of Annexin A6 via 




SLE, Systemic Lupus Erythematosus; MALDI-TOF, Matrix Associated Laser 
Desorption/Ionization-Time of Flight; ESI, Electrospray Ionization; Ro52 is also known 
as tripartite motif protein 21 (TRIM21). 





block and suggested potential mechanisms for the development of the condition 
[115,116].    
Haptoglobin α2 polypeptide chain differences have been noted between SLE and 
non-SLE populations via MALDI-TOF-MS [112].  Patients expressing the haptoglobin 
α2 isoform have been shown to have shorter survival times after coronary artery bypass 
graft [113] and more severe complications after myocardial infarction [114], possibly due 
to decreased ability to reduce oxidative stress.  The association of haptoglobin α2 
peptides with SLE flare may offer insight into the cardiac complications seen in SLE and 
higher levels of haptoglobin α2 have been reported in SLE patients vs. controls [112].    
To identify target autoantigens and explore the pathogenesis of dilated 
cardiomyopathy, Seko et al. [96] applied a 2-DE separation approach to plasma 
membrane proteins isolated from rat cardiac myocyte cultures.  The protein blot was then 
probed with serum of healthy controls as well as a 17 year-old patient with an unusual 
presentation of delayed cardiomyopathy subsequent to neonatal lupus erythematosus.  
While the control showed no significant reactivity, many immune-reactive spots appeared 
on the sample probed with SLE serum which were excised and analyzed on a LC-MS/MS 
system.  The analysis identified 2 high-probability proteins: annexin A6, known for 
calcium signaling and membrane trafficking, and vimentin, known for maintenance of 
cellular structure (Table 1).   
The authors downplayed the likelihood of vimentin playing a role in the 
pathogenesis of myocardial contractile dysfunction.  However, mice with overexpressed 





dilated cardiomyopathy [117], suggesting that if autoantibodies to annexin A6 stimulate 
its function, then the result would be suppression of myocardial activity.   
 
3.3 – Immune cell involvement in systemic lupus erythematosus 
SLE is, at its core, a disease of the immune system, so a deeper understanding of 
immune cell function in both normal and diseased states is critical for a comprehensive 
understanding of SLE.  Complementary studies by Dai [118] and Wang [109] show the 
evolution of a mass spectrometry-based interpretation of peripheral blood mononuclear 
cells (PBMCs) in SLE.  Dai et al. published their work in 2008 in which they compared 
the relative changes in the proteome of PBMCs of both healthy controls and SLE 
patients.  They employed the conventional approach of 2-DE and silver stain followed by 
MALDI-TOF/TOF to identify protein spots expressed at different levels.  A total of 20 
spots differed significantly between the SLE and control group with 11 being upregulated 
and 9 downregulated.  The findings of the study are summarized in Table 2.  Briefly, 
Immunoglobulin J chain, an early differentiation marker in B cells, was upregulated, as 
was calprotectin L1, a protein released by granulocytes and monocytes during activation.  
Interestingly, calprotectin L1 levels were associated with the severity of disease and at 
the same time were linked significantly to anti-dsDNA antibodies.  Glutathione S-
transferase was downregulated in SLE, which would reduce the cell’s ability to degrade 
reactive oxygen species, which may contribute to inflammation and tissue damage. 
Wang et al. [109] followed Dai two years later with an expanded study which 
employed the use of isobaric Tagging for Relative and Absolute protein Quantification 





Table 2 - Contributions of Mass Spectrometry to Immunological Biomarker 
Discovery in SLE 





• Upregulated in SLE 2.46 fold 






• Upregulated in SLE 2.02 fold  
• Known marker of disease activity in RA  
• Released from granulocytes and 
monocytes during their activation 
• Significantly tied to SLEDAI and higher 
levels of anti-dsDNA antibodies and 
SLE-arthritis 









• Downregulated in SLE 0.15 fold 
(p=0.001) in one study and vs. diseased 
and healthy controls 
• Lower GST results in higher ROS levels 
and increased oxidative stress 
Both 
Apolipoprotein A-
IV precursor [118] 
MALDI-
TOF 
• Upregulated in SLE 2.67 fold (p=0.010) 
• Similar results seen in RA [119] and 
Alzheimer’s Disease [120] 
Biomarker 
Zinc finger protein 
subfamily 1A [118] 
MALDI-
TOF 
• Upregulated in SLE 2.24 fold (p=0.041)  Both 
Zinc finger protein 




• Upregulated in active SLE vs. stable SLE 
(2.7160), RA (2.3824) and Healthy 
Controls (3.1042) 
Both 
Resistin [109] iTRAQ 2D 
LC-MS/MS 
• Upregulated in active SLE vs. stable SLE 
(3.6784) and Healthy Controls (2.2652) 
• Verifies Previous Findings 
Both 
S100-P [109] iTRAQ 2D 
LC-MS/MS 
• Upregulated in active SLE vs. stable SLE 
(2.9641), and Healthy Controls (2.6475) 
Both 
S100-A12 [109] iTRAQ 2D 
LC-MS/MS 
• Upregulated in active SLE vs. stable SLE 
(2.3374), RA (2.0595) 
Both 
Brain Acid Soluble 
Protein 1 [109] 
iTRAQ 2D 
LC-MS/MS 
• Upregulated in active SLE vs. stable SLE 




Substrate 2 [109] 
iTRAQ 2D 
LC-MS/MS 
• Downregulated in stable SLE (0.4663) 
vs. diseased controls 
Both 
SLE, Systemic Lupus Erythematosus; SLEDAI, SLE Disease Activity Index; Ig, 
Immunoglobulin; GST, Glutathione S-Transferase; LN, Lupus Nephritis; LC-MS/MS, 
Liquid Chromatography Tandem Mass Spectrometry; MALDI-TOF, Matrix Associated 
Laser Desorption/Ionization-Time of Flight; ESI, Electrospray Ionization 






used with LC-MS/MS to allow multiplexing of samples (up to 8 per run), which not only 
saves time, but also reduces technical variability.  Using 6 samples each for active SLE, 
inactive SLE, rheumatoid arthritis (RA) as a diseased control and healthy patient samples, 
452 proteins with a variety of cellular locations and biological functions were identified 
and quantified.  Of these, 126 were either upregulated or downregulated across all the 
groups.   When compared to the 2008 data, this study showed a similar downregulation of 
glutathione S-transferase and upregulation of zinc finger proteins with similar fold 
changes in both experiments, but also identified several other known SLE regulators and 
novel functional candidates.  In total, 17 proteins were upregulated and 13 were 
downregulated in active vs. stable SLE.  The author’s choices for future study are listed 
in Table 1.  Known SLE and inflammatory proteins were identified, such as resistin and 
calcium-binding family of S100 proteins.  Additionally, several novel candidate proteins 
were identified, such as brain acid soluble protein 1 and ras-related C3 botulism toxin 
substrate 2, which have roles in apoptotic mechanisms in other diseases [121,122], but 
this was their first link to SLE disease activity. 
 
3.4 – Lupus nephritis 
 
 Lupus Nephritis (LN) must be considered in a discussion on the use of proteomic 
methods in lupus, because LN is one of the most common and most severe complications 
that can arise from SLE (~50%), leading to significant morbidity and mortality [1].  As 
with other renal disorders, a major diagnostic source for LN is urine.  The advantage of 





nature of sample collection.  Urine studies also allow long-term observation of patients, 
allowing tracking of changes in the urine proteome associated with changing disease 
states.  SLE and LN biomarkers have been a topic of discussion dating back to the 1960’s 
and continue to be of interest today [111,123–125].  Recent proteomic studies have 
provided insight into novel urinary biomarkers for LN and are summarized in Table 3.   
Oates et al. [126] built on the ideas of urine protein quantification using 2-DE to 
train an artificial neural network capable of identifying potentially significant changes to 
urine proteomes immediately before validation by renal biopsy.  Briefly, 200 μg protein 
was collected from 20 different patients with SLE at the time of biopsy.  The recovered 
protein was denatured and separated using 2-DE.  A total of 213 protein spots across the 
20 patient gels were used to calculate protein abundance and an artificial neural network 
was trained to identify the class of LN based on the protein abundance profile.  The 
resulting neural network was able to successfully identify >86% of all positives and 
>92% of all negatives, with the exception of class V, where each false positive was 
present in a sample also positive for Class III or IV LN, which were correctly identified.  
The group then identified the most critical spots for determining sensitivity and subjected 
each to MALDI-TOF-MS, which identified 6 proteins: α-1 acid glycoprotein, α1 
microglobulin (2 spots), zinc α-2 glycoprotein (2 spots), and IgG κ light chain (Table 3).   
Early work successfully identified proteomic profiles of renal flare in SLE 
through the use of SELDI-TOF to identify protein signatures without the need to 
positively identify proteins. This allowed the identification of novel biomarkers, but the 
protein identification limitation of the SELDI-TOF technique prevented mechanistic 





Table 3 – Contributions of Mass Spectrometry to Biomarker Discovery in Lupus 
Nephritis 






















• Diagnosis and Class Identification of 
LN 
Biomarker 














• Upregulated in the urine at baseline and 
















• Upregulated in the urine 4 months pre-
flare 
Biomarker 
Aldolase A [111] LC-
MS/MS 
• Autoantibodies more common in LN 
patients than SLE without LN 
• Antibody specific to 94-183 aa epitope 
may be LN-specific biomarker  
Biomarker 
SLE, Systemic Lupus Erythematosus; LN, Lupus Nephritis; LC-MS/MS, Liquid 
Chromatography Tandem Mass Spectrometry; MALDI-TOF, Matrix Associated Laser 
Desorption/Ionization-Time of Flight; ESI, Electrospray Ionization; SELDI, Surface 
Enhanced Laser Desorption/Ionization 






mechanistic understanding of LN using longitudinal urine proteomics to assess the 
changes in the urine proteome before, during and after SLE renal flare by combining 
SLEDI-TOF with LC-MS/MS sequencing for protein identification.  Using a sample set 
of 145 urine specimens from SLE Class III, IV and V patients, they identified 27 low 
molecular weight proteins that showed significantly different levels of expression before, 
during or after SLE flare.  While no single peptide was present in all the flare or non-flare 
samples, combinations of two peptides were found that successfully differentiated 100% 
of the remission and pre-flare samples from flare and post-flare samples.  LC-MS/MS 
analysis identified multiple isoforms of α-1 Antitrypsin, albumin, and hepcidin as 
proteins of interest (Table 3).  Interestingly, Hepcidin-20 levels were only altered pre-
flare, which means Hepcidin-20 may be a useful indicator of impending flare, allowing 
modulation of clinical management to reduce severity and duration of the flare.  A follow 
up study two years later supported this idea and further presented IL-6 and INFα-
dependent upregulation of Hepcidin transcription as a possible mechanism of Hepcidin 
increase in LN [129]. 
A study using LC-MS/MS to characterize immune-reactive bands from 2-DE 
separated endothelial cell lysate with sera of SLE patients, other autoimmune conditions 
and healthy controls identified the glycolytic enzyme aldolase A as a candidate target 
antigen [111] (Table 3).  Moreover, this was found to be more common for LN patients 
than in SLE without LN (43.4% with LN vs. 11.1% without LN).  However, reactivity to 
aldolase A was not appropriately significant between LN and other inflammatory disease 





authors did however note specificity of LN patient anti-sera to the 94-183 aa region of 
aldolase A over other autoimmune conditions. 
Suzuki et al. used a combination of SELDI-TOF [130] and MALDI-TOF [131] 
for evaluation of the urine proteome in pediatric LN (Table 4).  Four potentially 
significant biomarkers were identified including transferrin (Tf), ceruloplasmin (Cp), α1-
acid-glycoprotein (AGP), and lipocalin-type prostaglandin-D synthetase (L-PGDS), each 
with great significance (p<0.005, Table 3).  Significant increases of Tf, L-PGDS, and 
AGP were seen as early as 3 months before clinical diagnosis or worsening of LN.  Both 
Tf and AGP were also seen in adult forms of the disease [132], while L-PGDS is novel to 
pediatric LN diagnosis.  Cp has been implicated in global SLE, but was not found to be 
an effective metric for defining the course of LN in pediatric patients.  
 
 
3.5 – Neuropsychiatric systemic lupus erythematosus 
 
Neuropsychiatric SLE (NPSLE) is a potentially severe complication that varies in 
its prevalence between 9.5%-95% based on the literature cited and the diagnostic criteria 
[133].  Findings suggest that NPSLE can be present in a mild form in as many as 95% of 
SLE patients [134], making it more common but typically less severe than renal or 
cardiovascular complications.  Mood disorders and cognitive disorders are common 
symptoms and can be particularly challenging to diagnose in pediatric and adolescent 
patients due to the rapid emotional and physical changes that occur at those ages.  While 





Table 4 - Contributions of Mass Spectrometry to Biomarker Discovery within 
Pediatric Populations of Lupus Nephritis Patients 








• Upregulated in worsening disease and 
flares in pediatric patients 
• Plasma Tf  related to global SLE 
activity 










• Upregulated in pediatric SLE and LN, 
but cannot specify between different 










• AGP from plasma is for global pediatric 
SLE  
• AGP from urine is specific to pediatric 
LN  









• Type prostaglandin-D synthetase (L-
PGDS) – role in chemotherapy induced 
renal damage (plasma and urine)  
• Novel to LN  
Biomarker 
Aldolase A [111] LC-
MS/MS 
• Anti-aldolase A antibodies have been 
found to be more common in SLE with 
LN than SLE without LN (43.4% to 
11.1%)  
• Possible specificity for other 
autoimmune conditions via presence of 
antibodies to the 94-183 aa epitope 
Biomarker 
SLE, Systemic Lupus Erythematosus; LN, Lupus Nephritis; Tf, Tranferrin; AGP, α1-
acid-glycoprotein (AGP); LC-MS/MS, Liquid Chromatography Tandem Mass 
Spectrometry; MALDI-TOF, Matrix Associated Laser Desorption/Ionization-Time of 
Flight; ESI, Electrospray Ionization; SELDI, Surface Enhanced Laser 
Desorption/Ionization 






diagnosis of many neurological diseases and therefore in addition to serum, CSF is a 
useful medium for proteomic study of NPSLE.  NPSLE research has focused on both 
biomarker identification for its diagnostic value as well as autoantigen identification for 
improved mechanistic understanding of the disease state and potential therapeutic 
development (Table 5). 
Lu et al. [94] found CSF and sera obtained from NPSLE patients to be reactive to 
rat, mouse and monkey brain homogenate when separated by 2-DE.  MALDI-TOF-TOF 
was used to identify immune-reactive proteins.  A total of 275 serum samples and 177 
CSF samples were included, giving a great deal of depth and statistical power to the 
study.  Briefly, four anti-ANA-positive serum samples, which did not react to Hep2 cells, 
were used as pilot samples.  Initial analysis of the reactive spots revealed an interaction in 
3 of 4 samples with α-internexin (INA), a highly conserved protein between rodents and 
humans (Table 5).  Recombinant human INA was then used in a western blot to confirm 
reactivity of sera as well as immunofluorescence with sera and anti-INA polyclonal 
antibody (pAb).  Both the sera and the pAb were found to react to cultured rat cortical 
neurons and the reactivity of sera was reduced by incubation with recombinant INA.  
These findings opened the door for analysis of the entire cohort of CSF and serum 
samples.  Using 2 standard deviations as a cutoff for positivity, 41.7% of the NPSLE 
samples of CSF were found to be positive for anti-INA antibodies (as compared to 0% of 
SLE with cerebral infarction, 7.1% of normal SLE controls, and 10% of other 
neurological diseases).  In total, the data showed reactivity in >40% of NPSLE patients in 
a dose dependent manner toward INA.  Longitudinal studies found that antibody levels 





Table 5 - Contributions of Mass Spectrometry to Biomarker Discovery in 
Neuropsychiatric SLE 








• Reactive antibodies found in NPSLE 
patient sera in 41.7% of patients (7.1% of 
SLE, 0% healthy controls and 10% of 
other neurological diseases) 





• Autoantibodies were found in 36% of 
NPSLE, (vs. 4% of SLE and 0% HC) 
• More frequently seen in severe (50%) 
than mild (20%) NPSLE 





• Previously identified in other autoimmune 
conditions such as multiple sclerosis and 
Guillain-Barre  
• Confirmed by LC-MS/MS [95]  
Both 
Crystalline αB [95] LC-MS/MS • Novel sera and CSF autoantigen for 
active NPSLE 
Both 
Esterase D [95] LC-MS/MS • Novel sera and CSF autoantigen for 
active NPSLE 
Both 
APEX nuclease 1 
[95] 
LC-MS/MS • Novel sera and CSF autoantigen for 
active NPSLE 
• More reactive in SLE than other 
autoimmune conditions 
Both 
60 kDa Heat Shock 
Protein [135] 
LC-MS/MS • Autoantibodies directed against cerebral 
lysates found in sera of NPSLE patients 
with WMH 
• Known to cause endothelial cell apoptosis 
and coronary artery disease 







LC-MS/MS • Found in 80% of NPSLE patient sera with 
psychosis (vs. 5.3% of NPSLE without 
psychosis and none of the CNS control 
samples) 
Both 
NPSLE, Neuropsychiatric SLE; CSF, Cerebral Spinal Fluid; WMH, White Matter 
Hypertrophies [on MRI]; CNS, Central Nervous System; LC-MS/MS, Liquid 
Chromatography Tandem Mass Spectrometry; MALDI-TOF, Matrix Associated Laser 
Desorption/Ionization-Time of Flight 






clinical remission.  Furthermore, mice immunized with INA plus LPS developed 
cognitive impairments similar to NPSLE and exhibited hippocampal and cortical neuron 
apoptosis, suggesting that the presence of anti-INA antibodies in the serum of patients 
was pathogenic. 
Ndhlovu et al. [136] identified α- and β-tubulin as target autoantigens for NPSLE 
using patient sera to probe isolated mitochondria from bovine brain followed by MALDI-
TOF analysis. Autoantibodies to β-tubulin have been identified in other CNS targeting 
autoimmune diseases such as Guillain-Barre syndrome, Multiple Sclerosis, and 
Sydenham’s chorea, but targeting of α-tubulin is potentially specific to NPSLE.  α-
tubulin autoantibodies were present in 36% of NPSLE patient sera, only 4% of SLE 
patients without neurological symptoms and none of the MS, epileptic or healthy control 
samples (Table 5).  Possibly due to the small size of the NPSLE population in the study 
(n=37), no correlation was seen between specific symptoms of NPSLE and the presence 
of α-tubulin autoantibodies in sera.  Larger patient population studies are needed to 
further explore the involvement of anti-α-tubulin antibodies in NPSLE. 
LC-MS/MS incorporates a direct front-end separation of complex samples to 
greatly increase the sensitivity of the procedure for low abundance protein detection.  LC-
MS/MS may be superior to MALDI-based techniques when dealing with complex 
samples.  Katsumata et al. found this to be true while attempting to uncover novel serum 
autoantibodies for SLE, in particular those involved in CNS syndromes [95].  Whole 
protein extracts from human neuroblastoma and glioblastoma cell lines were separated 
using 2-DE and reacted to patient sera.  It was determined that MALDI-TOF sensitivity 





sera from SLE patients with and without CNS syndromes was bound to Protein G-
Sepharose beads and incubated with the same cell line extracts.  Proteins pulled down 
with the Sepharose beads were analyzed with a LC-MS/MS method using a Q-TOF 
instrument.  Most of the 154 proteins identified by the LC-MS/MS approach were not 
identified in the 2-DE/MALDI-TOF analysis and 50 were found in the CNS group but 
not the non-CNS group.  After exclusion of previously described autoantigens, 11 
recombinant candidates showed reactivity against pooled serum of 28 patients with active 
CNS SLE by western blot analysis (5 of which were only detected by LC-MS/MS).  
These 11 candidates were then probed with sera of 106 SLE patients (42 with active CNS 
syndromes) as well as 100 healthy controls, resulting in a list of 5 confirmed 
autoantigens, 3 of which were novel (crystalline αB, esterase D and APEX nuclease 1, 
Table 1).  When compared to other diseased sera (RA, SSc, SS, and MS), levels of anti-
crystalline αB was not found to be significantly different. Anti-APEX nuclease 1 and 
esterase D, on the other hand, had significantly higher levels in SLE than in these disease 
controls and between CNS and non-CNS SLE sera.  APEX nuclease 1 is the major 
apurinic/apyrimidinic endonuclease in human cells and is found to be upregulated in 
tissues under oxidative stress and has a significant effect on apoptotic regulation in 
certain tissues [137].  The effects of esterase D are less well known. 
In a similar study, Kimura et al. used a combination 2-DE and LC-MS/MS with 
an ESI-LCQ instrument to obtain higher sensitivity for low abundance proteins [135].  
Patient sera from a NPSLE patient with white matter hyperintensities (WMH) on T2-
weighted MRI scan was reacted to a 2-DE rat cerebral lysate blot.  In total, 9 reactive 





corresponded to 60 kDa Heat Shock Protein (Hsp60) [135], which functions to refold 
proteins that are misfolded and/or facilitate degradation of proteins that cannot be 
recovered [138].  Enhanced expression of Hsp60 can induce endothelial cell apoptosis 
and Hsp60 expression on the surface of endothelial cells have been reported to be directly 
related to coronary artery disease [139], opening the possibility of a similar relationship 
in the cerebral vasculature.  In a follow-up study of 180 patients with neurological 
diseases (including 15 with SLE) and 23 healthy controls, Kimura et al. showed that the 
titer levels of anti-Hsp60 were directly correlated to severity of WMH in the brain, 
suggesting the presence of anti-Hsp60 as both a diagnostic tool as well as a mechanistic 
agent in the development of NPSLE [124]. Although the authors chose to focus on 
Hsp60, the study also found SLE specific antibodies to α-internexin, β-actin, and glial 
fibrillary acidic protein (Table 5). 
Another study using LC-MS/MS also suggested a relationship between NPSLE 
exhibiting psychosis with anti-Rab GDI-α [123].  LC-MS/MS and WB analysis of sera 
found that 4 of 5 patients with NPSLE with psychosis (80%) expressed anti-Rab GDI-α 
(Table 5), while 1 of 13 patients with NPSLE and none with psychosis (5.3%) expressed 
the autoantibody, along with no expression in patients with multiple sclerosis (n=12), 
infectious meningoencephalitis (n=13), polyneuropathy (n=10), psychotic syndromes 
(n=10), or healthy controls (n=12).   
 
 






Aside from assessing differences in disease states, pharmacologic reactions can be 
measured using proteomic techniques.  Kao et al. [140] used a 2-DE and MALDI-TOF to 
investigate the changes to apoptotic-prone macrophages (APM) from lupus-prone 
NZB/W-F1 mice before and after treatment with cystamine, a known inhibitor of 
transglutaminase 2 (TG2) activities.  A number of the findings indicated that cystamine 
has anti-apoptotic affect in the APMs and suggests possible mechanism of this activity.  
Protein expression and enzyme activity of Caspase 3 were downregulated and anti-
apoptotic proteins APIP, PEBP4, and Bcl-2 were upregulated.  ERK 1/2 showed reduced 
phosphorylation after treatment in APMs, which also would result in survival of APMs 
and fewer apoptotic bodies to serve as potential targets for autoantibody production.  
Previous studies have shown that ERK 1/2 phosphorylation is increased with cystamine 
treatment in endothelial cells [141] and neuronal tissue [142], therefore the findings of 
decreased phosphorylation in APM may help further explain the development of SLE in 
specific tissues and lead to a more complete model of pathogenesis.  
Mass spectrometry can also be useful as a supplemental technique of a study.  In 
work primarily focused on genetics, D’souza et al. [143] utilized MALDI-TOF-MS to 
support the hypothesis that catalase polymorphisms affect the risk and severity of SLE.  
Oxidative processes resulted in the 4-hydroxy 2-nonenol (4-HNE) adducts on membrane 
catalase of red blood cells (RBCs).  MALDI-TOF was of great use in this situation 
because it allowed the positive identification of catalase from RBC membranes (an 
uncommon location) while migrating at a higher molecular weight, possibly due to 4-
HNE adducts.  Ye et al. [144] expanded on previous microarray data by selecting a gene 





creating a IFIT1 fusion protein with GST, and then using bead immobilized GST-IFIT1 
as bait to capture interacting proteins in white blood cell lysate.  MALDI-TOF was 
performed on the proteins pulled down in the procedure and found Rho/Rac guanine 
nucleotide exchange factor to be a potential target for IFIT1 interaction in SLE.  Follow 
up studies have supported the role of the interferon pathway in SLE and other 
autoimmune diseases [145–147].  
 
3.7 – Characterization of the Secretome of Cultured Cells 
 
Cell culture provides an opportunity to isolate a cell type from the organism to 
analyze its function in a controlled setting.  It is not possible to replicate all biological 
events which would take place in a mammalian system, but experimental models utilizing 
cell culture for initial discovery can be useful to identify low abundant targets or factors 
from specific cell populations which would otherwise be masked in a typical body fluid 
sample.   
The global hypothesis of this dissertation succinctly states that podocyte activity 
can promote the development of GN, and that ABIN1 is important to prevent 
inflammation in local tissues.  This is not, however, to say that cells of the immune 
system are not involved.  NF-κB-mediated signaling events in mesangial cells and 
podocytes are known to promote synthesis and secretion of pro-inflammatory cytokines 
and chemokines which recruit neutrophils, macrophages and other immune cells to 
tissue[148–152].  Normal immune cell functions in these tissues include clearing of 





podocytes and mesangial cells to otherwise healthy tissue can lead to inflammatory 
damage.  The renal secretome is an incompletely characterized collection of factors 
released by the cells of the kidney[152].  We characterized the normal secretome of 
podocytes and simultaneously investigated ABIN1-related changes to the secretome 
which may attract excessive numbers of immune cells to the kidney, resulting in local 
conditions which may promote LN [148–151,153–158].  This was accomplished through 
a relatively unbiased analysis of the secretome of each cell type under varying conditions 
with two-dimensional liquid-chromatography tandem mass spectrometry (2D-LC-
MS/MS).     
Method development focused on establishing a sample of appropriate purity but 
with sufficient chemical properties suitable for LC-MS/MS analysis.  Three factors were 
of great importance:  (1) the chosen stimulant, TNF-α, could mask low abundant 
cytokines via ion suppression and additionally would hinder measurement of TNF-α 
produced by the podocyte, (2) the proteomic makeup of the cell culture media would 
have to be sufficient for LC-MS/MS analysis, and (3) the media had to be sufficient for 
proper podocyte cell functions and could not induce unnecessary stress on the cells which 
would undoubtedly affect their inflammatory profile.  Podocyte cell culture media is 
comprised of 10% FBS, which contains a host of protein “contaminants”, and phenol red 
can confound LC-MS/MS analysis and should be avoided.  In addition to the chemical 
components of the media, the timing of stimulation and sample collection need to be 
optimized for each cell type used and for each stimulant.   Following a number of 
preliminary experiments, I arrived at a protocol which accomplished all of these 





free media, followed by 3 washes in 10mL warm Krebs buffer, and a 6 hour collection in 
warmed Krebs buffer.  Figure 8 outlines the kinetic properties of cultured podocytes 
stimulated from 0-18 hours with TNF-α and shows that a 6 hour stimulation was 
sufficient to induce production of 3 important proinflammatory cytokines, MCP-1, GM-
CSF, and IL-8.  In addition, I also was able to remove the TNF-α used for stimulation to 
below detectible levels of our ELISA assay (<<2 pg/mL).  This was important for both 
LC-MS/MS analysis as well as downstream characterization of these samples using 
biological methods (see Chapter V).   
Once optimal timing and media components were achieved, sample analysis had 
to be addressed.  Most cytokines are small proteins and we have found that sample purity 
is increased through a 10 minute centrifugation in an Amicon Ultra-30kDa Centrifugal 
Filter Unit (Millipore, Billerica, MA) to remove proteins larger than 30 kDa, followed by 
standard trypsin digest and LC-MS/MS sample preparation as described in the materials 
and methods.  Figure 9 shows protein identifications without this cutoff and includes a 
number or large, high abundant proteins such as fibronectin and actin.  Figure 10 outlines 
proteins identified after the 30 kDa cutoff was applied before trypsin digestion.  A 
number of cytokines expected to play a role in GN are shown to be upregulated in the 
podocyte secretome, including IL-6, MCP-1 (CCL2) and the cell adhesion molecules 
VCAM1 and ICAM1.  The benefit of mass spectrometry-based approaches is the ability 
to identify novel proteins from a given sample, and a number of promising candidates for 
future study were identified such as transgelin and TIMP1 which have a role in matrix 






Figure 8 – Kinetics of Cytokine Secretion by Podocytes in Response to TNF-α 
Stimulation 
Podocytes were produced and treated as described in the Materials and Methods.  
TNF-α stimulation (100ng/mL) at time points from 0-18 hours was used to 
determine the kinetics of cytokine production using ELISA to measure cytokine in 
pg/mL.  It was found that from 0-6 hours of TNF-α stimulation, TNF-α response 
resulted in high levels of cytokine production.  Further, the wash step following the 
18 hour time point resulted in all analytes dropping below their detectible level for 
their respective assays, and this included TNF-α which was the stimulant. 





 Figure 9 - Identification of Total Protein Secreted from Cultured Podocytes 
Cell culture supernatant was prepared from cultured podocytes as described, 
digested and prepared for LC-MS/MS analysis.  Identified peptides were 
predominantly highly abundant matrix proteins and large cytosolic proteins, rather 
than the typically small (<30kDa) cytokines and chemokines.  This analysis 
identified 932 proteins and 35,075 unique spectra. 






Figure 10 – Identification of Proteins Secreted by Podocytes Following 30 kDa 
Size-Selective Filtration 
Most cytokines and chemokines are small peptides of less than 30 kDa.  Thus, to 
prevent contamination and ion suppression from highly abundant proteins, an Amicon 
Ultra-30kDa Centrifugal Filter Unit from Millipore was used to remove proteins larger 
than 30 kDa before tryptic digestion.  The heatmap represents the Protein Abundance 
Factor (PAF) which provides a quantitative value for each identified peptide while 
taking into account the total protein’s size, with the understanding that larger proteins 
will produce more digested peptide fragments and thus will artificially result in higher 
numbers of peptide identification.   
Erik Korte.  Unpublished.   
Symbol WT D472N WT D472N
VIM  120.960 65.491 101.780 68.065
IL6  5.125 6.742 4.425 10.256
TAGLN  5.125 12.520 6.638 16.783
HSPG2  18.451 52.008 17.701 61.538
SCRN1  1.025 2.889 1.106 4.662
GREM1  3.075 9.631 4.425 8.392
LGALS3BP  1.025 10.594 1.106 8.392
SERPINH1  5.125 9.631 5.532 9.324
CNN3  6.150 10.594 4.425 10.256
LUM  5.125 9.631 4.425 10.256
ANXA3  4.100 7.705 2.213 10.256
TMSB4X  13.326 22.151 17.701 11.189
SERPINA1  18.451 29.856 21.020 38.228
MSN  29.726 41.414 42.040 50.350
STIP1  13.326 10.594 12.169 7.459
FLNC  12.301 9.631 8.850 7.459
CFL1  37.927 15.410 29.870 13.986
TPT1  2.050 6.742 4.425 4.662
CCL2  4.100 3.852 5.532 4.662
COL4A1  1.025 8.668 1.106 4.662
ILF3 4.100 5.779 6.638 5.594
BMP1  1.025 4.816 1.106 5.594
C1S  2.050 5.779 1.106 5.594
NPC2  3.075 2.889 2.213 5.594
VCAM1  0.000 0.000 1.106 5.594






moesin has suggested it may be directly involved in the pathogenesis of GN as an 
autoantigen for a small population of patients with membranous glomerulonephropathy.   
 
 
3.8 – Conclusions 
 
Many of the studies presented in this review were aimed at using proteomic applications 
to define events in specific SLE complications, but it is our view some of these 
discoveries could also provide insight into other areas of SLE or that approaches applied 
to similar diseases could be modified for use in SLE.  Recent studies have shown the use 
of MALDI-TOF techniques for synovial fluid analysis in autoimmune arthritis [159], 
which could be used to assess changes in SLE arthritis.  Kimura et al. [135] identified a 
60 kDa Heat Shock Protein as an autoantigen in NPSLE, a protein with known ties to 
coronary artery disease and endothelial cell apoptosis [139,160,161] which may play a 
role in the development of cardiovascular SLE.  Several studies have shown the benefits 
of proteomics using bronchoalveolar lavage fluid (BALF) as a sample for the study of 
sarcoidosis [162], systemic sclerosis [163,164], and other pulmonary diseases [165,166].  
The use of BALF for the study and diagnosis of pulmonary complications in SLE would 
be less invasive and safer than biopsy.  Tamburro et al. [167] recently published a 
proteomic review of the vitreous humor of the eye.  Contrasting these findings to the 
proteome of SLE patient’s vitreous humor could shed more light on the pathogenesis of 
retinopathy in SLE. Dai et al. [118] found Immunoglobulin J to be upregulated in 





used such as multiple reaction monitoring (MRM) and Selected Reaction Monitoring 
(SRM) LC-MS/MS, which allows focused study on only m/z ratios of interest, reducing 
sample processing time and greatly increasing throughput.  After the initial biomarker 
discovery stages, MRM/SRM has been used as a tool in biomarker validation in blood 
[168] and synovial fluid, specifically in RA patients [169].  Additionally, the speed and 
potential for multiplexing means MRM/SRM could have clinical utility in patient 
diagnosis, prognosis, and monitoring [170].  We used a LC-MS/MS approach to identify 
the M-type phospholipase A2 receptor (PLA2R) as the target antigen in idiopathic 
membranous nephropathy (iMN) [5]. Antibodies recognizing the PLA2R were present in 
70% to 80% of iMN patients.  However, they are not present in any patients with 
membranous lupus nephritis (MLN), which develops in up to 40% of patients with LN 
[171].  This suggests that there are unique autoantibodies directed against specific kidney 
proteins other than the PLA2R in MLN. Therefore, proteomic studies could be designed 
to identify such target antigens as well as specific epitopes important in MLN.   
Even with the strides we have made in the understanding of SLE, it is still a 
debilitating condition effecting hundreds of thousands of patients every year.  While 
treatments are available, they bring with them significant side effects and frequent failure 
rates.  Recent advances in mass spectrometry technology have allowed an even more 
thorough analysis of complex samples to better understand the significance of minute 
changes in the pathogenesis of SLE, while accommodating large sample sizes through 
multiplexing and high throughput methods.  The method I outline here can serve as a 
starting point for optimization of LC-MS/MS analysis for the secretomes of many diverse 





researchers or clinicians have in mass spectrometry techniques are rapidly expanding and 
have the ability to be tailored to a specific study.  It is my hope that the characterization 
of the potential applications of mass spectrometry will provide a greater knowledge of the 
diverse uses of mass spectrometry and other proteomic technologies in the study of SLE, 
GN and other conditions.  While a proteomic understanding of disease is by no means a 
panacea, it offers the potential to help advance our knowledge and understanding of SLE 














ABIN1 DYSFUNCTION AS A GENETIC BASIS FOR LUPUS NEPHRITIS 
 
4.1 – Introduction 
 
 As stated previously, SLE is a multi-system autoimmune disease that is 
characterized by an abnormal immune response leading to autoantibody production, 
immune complex formation, T cell activation, and inflammatory cytokine release [8]. 
Multiple factors contribute to SLE and LN is a frequently associated condition which is 
devastating to the patient [8,10].  The pathogenesis of LN is variable among different 
ethnic groups showing a genetic link, but current therapies are ineffective in half the 
population and carry major side effects [4,14].   
Our lab has previously characterized SLE-like autoimmunity in a mouse model 
expressing ABIN1[D485N] [53].  Due to the more than casual relationship between SLE 
and LN, I asked if these mice could present a renal phenotype which would shed light on 
the major glomerular events in the pathogenesis of LN.  A major symptom of renal 
dysfunction is protein loss into the urine from resulting from glomerular damage [16].  





measure the serum protein albumin against the level of creatinine in the urine which is 
freely filtered into the urine and not secreted to a great degree by tubule cells, and thus 
provides an appropriate normalization factor for glomerular filtration compared to 
reabsorption of water in the tubules [172].   
Physiological changes in both mouse models and human disease include foot 
process effacement and expansion of the mesangial matrix and will be described in this 
spontaneous model of autoimmunity to further suggest a GN-like phenotype [17].  
Complement component 3 (C3) plays a central role in the innate immune response and 
inflammation, and low serum C3 is a diagnostic criteria for SLE [173].  Here I seek to 
characterize the changes in this model of spontaneous autoimmunity as it pertains to 
human disease, and begin to identify the molecular mechanisms responsible for the 




4.2 – Results 
 
Renal Pathophysiology of ABIN1[D485N] knock-in mice 
We reported previously that ABIN1[D485N] mice develop antibody-mediated 
glomerulonephritis [53]. The aim of this study was to provide a complete characterization 
of the renal abnormalities in these mice.  Table 6 presents the evaluation of the histologic 
grading of glomerular changes in wild-type (WT) and ABIN1[D485N] mice at 3-4 











































































































































































































































































































































































































































































































described in Chapter 2. Glomerular size, mesangial and endocapillary proliferation, and 
mesangial expansion in ABIN1[D485N] mice were all significantly increased by 3-4 
months. By 5-6 months ABIN1[D485N] mice demonstrated a significantly progressive 
increase in glomerular size, endocapillary proliferation, and mesangial expansion, when 
compared to 3-4 month old ABIN[D485N] mice (Figure 11a).  All mice at 3-4 months of 
age demonstrated glomerular hypercellularity, with 50% showing severe (3+) changes.  
Hypercellularity was focal in 2 mice and diffuse in 9. At 5-6 months all mice showed 
diffuse hypercellularity and all but one were histologically graded as severe (3+).  An 
increase in mesangial matrix was seen in 8 of 11 mice at 3-4 months, but was only mildly 
increased in 3 of those 8 mice.  At 5-6 months, all but one mouse demonstrated a 
moderate to severe increase in mesangial matrix.  Crescents were only observed in 2 mice 
at 5-6 month, and glomerular sclerosis was seen in 4 of those mice.  
Table 6 and Figure 11b show that there was a significant amount of interstitial 
inflammation in ABIN1[D485N] mice at 3-4 months of age, while little or no tubular 
atrophy or interstitial fibrosis was observed.  By 5-6 months, there was a significant 
increase in interstitial inflammatory cell infiltration, tubular atrophy and interstitial 
fibrosis (Figure 11b).  Mild interstitial inflammation was seen in only 4 of 11 mice at 3-4 
months.  By 5-6 months, all mice had some degree of interstitial inflammation, which 
was moderate or severe in 8 of 11 mice.  Mild, patchy tubular atrophy was seen in less 
than 50% of mice in each age group.  A sparse amount of tubulointerstitial fibrosis (TIF) 





Figure 11 – ABIN1[D485N] Mice Develop Severe Progressive GN 
Glomerular, interstitial, and tubular pathology was assessed by evaluation of a complete 
cross- section of an entire kidney in a blinded manner. Glomerular damage was assessed 
by semiquantitative scoring of size, cellularity, mesangial matrix expansion, crescent 
formation, and sclerosis on a 0 (normal), 1+ (mild abnormality), 2+ (moderate 
abnormality), and 3+ (severe abnormality)  scale. The semiquantitative scoring of  
interstitial  inflammatory cell infiltration, interstitial fibrosis, and tubular atrophy was 
based on the percentage of interstitium area affected: 0, normal; 1+, <25% of interstitial 
cross-section affected; 2+, 25%–50% of interstitium affected; 3+, >50%  of interstitium 
affected in a single cross-section of an entire kidney. An activity index was calculated as 
the sum of individual scores for glomerular size, glomerular hyper- cellularity, cellular 
crescents, mesangial expansion, and interstitial inflammation. We also determined 
whether the lesions were focal (involving <50% of the glomeruli) or diffuse (involving 
>50% of the glomeruli). 







mice at 5-6 months. There were no differences in histologic injury between male and 
female mice.  
Figure 12 shows that the urine albumin to creatinine (UAC) ratio was 
significantly elevated in 3-4 month old ABIN1[D485N] mice compared to WT. The urine 
albumin excretion did not increase further in 5-6 month old ABIN[D485N] mice. 
Surprisingly, serum C3 was found to be significantly higher in 3-4 month old 
ABIN1[D485N] animals compared to WT mice, but C3 was markedly decreased in the 5-
6 month old ABIN1[D485N] mice (Figure 13). Our previous study showed that 
antinuclear antibodies were present by 3-4 months of age in ABIN1[D485N] mice [53]. 
The following figures include representative examples of the histology depicted in 
Table 6 and Figure 11.  Figure 14b shows a glomerulus from an ABIN1[D485N] mouse 
at 4 months of age demonstrating mild mesangial and endocapillary hypercellularity with 
little or no mesangial matrix expansion or interstitial inflammatory infiltrate, and Figure 
14a shows a glomerulus from a WT mouse for comparison. Figure 14c shows a 
glomerulus from a WT 6 month old mouse.  Figure 14d, Figure 15, and Figure 16 show 
the more severe glomerular changes seen in 5-6 month old ABIN[D485N] mice.  Figure 
14d shows a glomerulus with moderate mesangial and endocapillary cell proliferation 
and a thickened capillary loop wall typical of “wire loops” (arrow). Figure 15 shows an 
example of severe glomerular hypercellularity, marked mesangial matrix expansion, and 
severe interstitial cell infiltration (arrow).  Figure 16 shows a glomerulus with crescent 
formation (arrow), glomerular sclerosis, and interstitial fibrosis.  
Figure 17a shows a transmission electron micrograph (TEM) from a 6 month old 





Figure 12 – Urine Albumin to Creatinine is Elevated in ABIN1[D485N] Mice 
Urine albumin-to-creatinine ratio of 3- to 4-month-old and 5- to 6-month-old 
ABIN1[D485N] and WT mice (total n=82) show significant protein loss into the urine 
by 3-4 months of age in ABIN1[D485N] mice compared to ABIN1 WT.  Significance 
was calculated using Mann-Whitney rank order analysis (* p<0.05 and ** p<0.001). 







Figure 13 – Complement Component 3 Levels are Reduced in Late Disease 
Reduced serum C3 levels are a clinical sign and diagnostic factor of SLE.  Using the 
same cohort as that described in Figure 12, serum C3 levels were assessed and found to 
be lower than WT mice in older animals, although higher than WT in the younger 
animals.   Significance was calculated using Mann-Whitney rank order analysis (*** 
p<0.0005). 







Figure 14 – Renal Histology of WT and ABIN1[D485N] Mice 
Renal histology in wild-type and ABIN1[D485N] mice. (A) 100X magnification of a 
Periodic acid-Schiff (PAS) stained kidney section from a 3-4 month old wild-type (WT) 
mouse. (B) A comparative 100X PAS image shows that at 3-4 months the 
ABIN1[D485N] mouse kidneys display mesangial hypercellularity, matrix expansion and 
capillary loop thickening as compared to WT mouse kidneys. (C) 100X magnification of 
a Periodic acid-Schiff (PAS) stained kidney section from a 5-6 month old wild-type (WT) 
mouse. (D) A comparative 100X PAS image shows that at 5-6 months the 
ABIN1[D485N] mouse kidneys display severe mesangial hypercellularity, matrix 
expansion and “wire loops” (arrow) compared to WT mouse kidneys.  







Figure 15 - ABIN1[D485N] Mice Exhibit Interstitial Inflammation 
Representative 40X magnification PAS stain showing glomerular injury and extensive 
interstitial immune cell infiltration (arrow) observed in 5-6 month ABIN1[D485N] mouse 
kidneys. 







Figure 16 - ABIN1[D485N] Mice Exhibit Interstitial Fibrosis 
Representative 40X magnification of Masson's trichrome staining showing examples of 
tubuleinterstitial fibrosis, glomerular fibrosis and crescent formation (arrow) and immune 
cell infiltration (lower right corner) in 5-6 month ABIN1[D485N] mouse kidneys. 






Figure 17 - ABIN1[D485N] mouse glomeruli display mesangial and subendothelial 
deposits. 
(A) TEM image of WT mouse kidney (large arrow, erythrocyte; small arrow, endothelial 
cell). (B) Minimal mesangial expansion and immune deposits (small arrows) in a TEM 
image of a 4-month-old ABIN1[D485N] mouse kidney. Podocyte foot processes are 
intact. The large arrow points out a monocyte in a capillary. (C) Extensive mesangial 
expansion and immune deposits (small arrows) in a TEM image of a 6-month-old 
ABIN1[D485N] mouse kidney. The large arrow points out a monocyte in a capillary. (D) 
Example of subendothelial immune deposits (long small arrow), areas of podocyte 
effacement (short small arrow), and mesangial immunoglobulin deposits (large arrow) in 





demonstrating moderate mesangial expansion and small electron dense deposits in the 
mesangium (small arrows).  Podocyte foot processes are intact. The large arrow points 
out a monocyte in a capillary.  TEM in Figure 17c shows extensive mesangial expansion 
and mesangial deposits in a 6 month old ABIN1[D485N] mouse kidney (small arrows). 
The large arrow points out a monocyte in a capillary.  Figure 17d shows a TEM from a 6 
month old ABIN1[D485N] mouse demonstrating subendothelial (long, small arrow) and 
mesangial (large arrow) electron dense deposits and focal foot process effacement (short, 
small arrow).  
Figure 18 shows immunofluorescence (IF) images of 5-6 month ABIN1[D485N] 
kidneys demonstrating IgG, IgA, IgM, C3, and C1q deposition along capillary loops and 
in the mesagium. IF from 3-4 month old ABIN1[D485N] mouse kidneys showed mild 
deposition of immunoglobulin and complement within the mesangium (not shown).   
Our results show that loss of ABIN1 function in NF-κB activity is associated with 
the development of proteinuria and proliferative glomerulonephritis with features typical 
of class III and IV LN. Those changes become progressively worse between 3 and 6 
months, at which time they are associated with low serum C3 levels. From our animal 
data, we postulated that genetic alterations in ABIN1 leading to dysregulation of NF-κB 
and MAPK activation could be involved in the development of LN. This hypothesis led 
us to evaluate SNPs in the gene for ABIN1, TNIP1, in SLE patients with and without LN. 
 
Association of TNIP1 SNPs and Human Lupus Nephritis 
To investigate a clinical relevance for ABIN1 dysfunction in human lupus nephritis (LN), 






Figure 18 - Deposits in ABIN1[D485N] glomeruli contain complement factors and 
immunoglobulins. 
The panels show examples of the immunofluorescence staining that was observed for the 
different labeled complement factors and immunoglobulin subtypes in kidneys from 5 to 
6-month-old ABIN1[D485N] mice. No significant immunofluorescence was observed 
for age-matched WT mice. 






genotyped in a total of 16,999 individuals of European-ancestry (EA), African American 
(AA), Asian, Gullah and Hispanic as described in Chapter 2 (Table 7) ([65]). After 
applying quality control assessment, we studied 15,864 individuals consisting of 3,089 
SLE cases with LN, 4,308 SLE cases without LN, 1,097 SLE cases with unknown status 
of LN, and 7,492 healthy controls (Table 8). To evaluate evidence for genetic association, 
we performed single-marker logistic regression analysis adjusting for gender and global 
ancestry estimates. Comparing SLE cases with lupus nephritis to SLE cases without LN 
(case/case analysis) showed strong associations surpassing the Bonferroni corrected 
significant threshold P < 0.01 at rs7708392 in EAs (P = 3.66 x 10-4, odds ratio (OR) = 
1.22) and rs4958881 in AAs (P = 8.47 x 10-3, OR = 1.22) (Table 9). No SNPs reached the 
Bonferroni corrected significant threshold in other populations. Analysis of SLE cases 
with LN versus healthy control subjects confirmed the validity of our case only analysis 
(rs7708392 in EAs: P = 1.82 x 10−11, OR = 1.44; rs4958881 in AAs: P = 4.43 x 10-3, OR 
= 1.20). Overall, our results indicate that polymorphisms in the region of TNIP1 are 
associated with LN in EAs and AAs.   
 
 
4.3 – Discussion 
 
 Here I show that a knock-in mouse expressing an ABIN1 mutant, 
ABIN1[D485N], with impaired negative regulation of NF-κB, developed progressive, 
proliferative glomerulonephritis with histologic features of class III and IV human lupus 






Table 7 - Sample summary before quality control adjustments. 
 
 































































































American 8066 3818 1243 2306 699 1642 6403 21 
African-
American 3462 1893 636 663 270 723 2733 6 
Asian  2676 1348 561 633 134 296 2380 0 
Gullah 286 131 70 80 5 34 252 0 
Hispanic 2509 887 702 823 97 227 2279 3 

























































































American 7427 3491 1129 2161 646 1495 5932 
African-
American 3338 1811 709 704 234 695 2643 
Asian 2525 1260 529 610 126 253 2272 
Gullah 275 123 70 79 3 33 242 
Hispanic 2299 807 652 754 88 207 2092 























































































human LN. A role for NF-κB in the incidence and severity of LN was suggested 
previously by the correlation of enhanced NF-κB protein expression in disease kidney 
sections or reduction of disease phenotypes in animal models after administration of 
compounds that indirectly inhibit NF-κB signaling [30–34]. Although the mechanisms 
regulating those effects of NF-κB on LN have not been determined, these data provide a 
potential mechanism for NF-κB dysregulation in some patients with LN.  
K63 and linear polyubiquitin conjugation mediates a number of protein-protein 
interactions required for activation of the IκB kinase (IKK) complex and hence NF-κB 
transcription [56,174–176]. ABIN1 contain a polyubiquitin binding domain (UBD) that is 
also present in NEMO, termed UBAN (Ubiquitin-Binding domain in ABIN proteins and 
NEMO) [62]. . The UBAN in ABIN1 contains a highly conserved region consisting of 
amino acids 472-480 in humans and 485-495 in mice [62]. The Asp to Asn mutation at 
this conserved residue 485 (mouse) or 472 (human) of the UBAN renders ABIN1 
incapable of binding recombinant Lys63 and linear polyubiquitin chains and 
polyubiquitinated NF-κB activators from cell lysates [44,50,51,53,62]. We previously 
reported that ABIN1[D485N] knock-in mice have enhanced NF-κB signaling in B cells 
and bone marrow-derived macrophages and developed a SLE-like autoimmune disease, 
with enlarged spleens and lymph nodes, elevated levels of pathogenic immunoglobulins, 
and antinuclear antibodies in the serum as early as 4 months of age [53]. The present 
report shows that those mice develop proteinuria by 3-4 months of age, 
hypocomplementemia by 5-6 months, and renal histologic abnormalities including focal 
and diffuse glomerular hypercellularity involving both endocapillary and mesangial cells, 





walls, immunoglobulin (IgG, IgA, and IgM) and complement deposition in a mesangial 
and capillary loop pattern, and mesangial and subendothelial electron dense deposits by 
electron microscopy. Those findings suggest that ABIN1[D485N] knock-in mice provide 
a model of human SLE, including the development of class III/IV LN. Our model 
indicates that SLE and LN can be initiated by disruption of ABIN1 NF-κB inhibitory 
function, at least in part, in B cells. Another recent report showed that ABIN1-deficient 
mice develop progressive lupus-like autoimmune phenotypes and glomerulonephritis 
[52]. In addition to NF-κB activation, we also showed in a previous report that JNK and 
p38 MAPK signaling was enhanced after stimulation with TLR agonists in B cells, bone 
marrow-derived macrophages (BMM), and dendritic cells isolated from ABIN1[D485N] 
mice [53]. A role for enhanced MAPK signalling in the development of 
glomerulonephritis (GN) has been suggested in several reports [177–180]. Stambe et al. 
showed that there was enhanced active p-p38 MAPK in glomeruli, tubules, myofibroblast 
and infiltrated neutrophils and macrophage in kidney biopsies from patients with 
different types of proliferative GN, including class III/IV LN and that elevated p-p38 
MAPK correlated with renal dysfunction and histopathology [180]. The same group 
showed in a separate study that administration of a specific p38 MAPK inhibitor 
prevented renal injury and renal function loss from anti-glomerular basement membrane 
(GBM)-induced GN in rats [179]. Another report showed that proteinuria and glomerular 
cell proliferation-induced by anti-GBM was dependent on JNK activity in bone-marrow 
macrophages [177]. Taken together, the present study and the previous reports support 
the hypothesis that loss of ABIN1 K63 and linear polyubiquitin binding results in 





Variants in the ABIN1 gene TNIP1 have been reported in SLE patients, 
suggesting a role for ABIN1 in human autoimmune disease [65,67,68]. Gateva et al. 
showed an association for a TNIP1 variant (rs7708392) in European-Ancestry American 
and Swedish SLE patients [67]. Han et al. also reported a TNIP1 variant (rs10036748) in 
a Chinese Han SLE population [68]. This SNP also showed significant association with 
European population, and the frequency (77%) was much higher in the European 
population than in the Chinese population (26%) [68]. Both of these variants are in non-
coding regions of TNIP1, and the functional consequence and association with LN were 
not reported. The associations of those TNIP1 variants were also replicated in Japanese 
(rs7708392) and Chinese Han (rs10036748) populations [181,182]. There was a stronger 
association for rs7708392 with LN in the Japanese population [181]. A replicate study of 
rs7708392 and rs10036748 in a southwest Chinese SLE population found a weak 
association, but as for the Japanese population, a significant association for rs7708392 
with LN in their SLE population was apparent [69]. Consistent with those previous 
reports, the current study found association (P = 3.66 x 10-4, odds ratio (OR) = 1.22) for 
rs7708392 when comparing American SLE patients of European-Ancestry with LN vs. 
those without LN, but this association was not significant in African, Asian or Hispanic 
American cohorts. The discord for the finding in our Asian cohort and the reported 
finding in southwest Chinese and Japanese populations with regards to LN association 
may be explained by the composition of our Asian population of 1012 total patients, 
which was 90% Korean. The present report also identified association for another TNIP1 
variant (rs4958881) (P = 8.47 x 10-3, OR = 1.22) in African American SLE patients with 





systemic sclerosis (SSc), but not SLE [71]. Additionally, ABIN1 expression was 
decreased in SSc skin lesions and in dermal fibroblast from SSc patients, compared to 
controls, and transgenic expression of ABIN1 abrogated matrix protein expression 
induced by inflammatory cytokines in fibroblast from SSc patients [71]. This suggests 
that the rs4958881 variant could result in lower renal expression of ABIN1 in LN, 
leading to increased mesangial cell matrix production typically seen in class III and IV 
LN in humans [10] and found in the ABIN1[D485N] knock-in mice.  
 In summary, these data suggest that mutations in ABIN1 represent a new genetic 
basis for LN through the novel pathophysiologic mechanism of aberrant regulation of 
NF-κB and MAPK activity (Figure 19). This is supported by knock-in mice expressing a 
mutation of ABIN1 with loss of NF-κB and MAPK inhibitory function and a strong 
association of a novel TNIP1 polymorphism and LN in a SLE patient population with a 
higher incidence of LN. Our findings support an association between polymorphisms in 
TNIP1 and the development of LN. This mouse model closely replicates the human 
disease and, therefore, potentially serves as an effective tool to study diagnostic and 








Figure 19 - ABIN1 aberrant regulation of NF-κB and MAPK signaling in LN. 
Pro-inflammatory gene activation is mediated by activation of the upstream I kappa B 
kinase (IKK) complex or MAPK kinases (MKK) activation of JNK or p38 MAPK. IKK 
and MKKs are activated by an Inflammatory Activating Complex (IAC) consisting of 
IRAKs, TRAFs, RIPs, and TAK1, among others. ABIN1 binds to K63-linked and linear 
polyubiquitin chains and inhibits components of the IAC or IKKγ.  










ABIN1 DETERMINES THE SEVERITY OF ANTIBODY-MEDIATED 
GLOMERULONEPHRITIS THROUGH A NOVEL PODOCYTE-NEUTROPHIL AXIS 
 
5.1 – Introduction 
 
Proliferative glomerulonephritis (GN) is an important cause of end-stage renal 
failure [183].  The current paradigm for the pathogenesis of GN is that immunoglobulin 
deposition in the glomerulus, in the form of immune complexes or autoantibodies against 
constituents of the glomerulus, initiates a proinflammatory response through Fc receptor 
(FcR) ligation and activation of the complement cascade, leading to immune cell 
recruitment and activation.  Mesangial cells respond to immunoglobulin and complement 
by regulating the glomerular microenvironment through the production of various 
cytokines and chemokines, resulting in increased endothelial cell expression of adhesion 
molecules that recruit and activate leukocytes [15,18].  Although inflammatory injury 
leads to podocyte dysfunction, the response of podocytes to immunoglobulin and/or 
complement deposition and their contribution to the inflammatory response are poorly 
understood, and only a few authors have published work to expand this field [22,23].  





actively participate in the modulation of the immune response.  If podocytes can be 
shown to provide the cytokines and chemokines that influence glomerular inflammation, 
this may open up therapeutic avenues never before considered.   
It is well established that neutrophils are pathogenic protagonists in antibody-
mediated GN, although recent effort has focused on cells that function in a more classic 
immunoregulatory role, such as monocytes, B-cells, T-cells, and dendritic cells [23–29].  
Neutrophil granules contain both reactive oxygen species and proteases that cause injury 
to vascular tissue when released, and the glomerulus is in the unique situation to be 
constantly patrolled by neutrophils [25–28].  Still, direct injury of podocytes by 
neutrophils has not previously been evaluated.   
As highlighted previously, NF-κB activation is associated with GN and is 
important to podocyte response to proinflammatory stimulation [35–37].  Inhibition of 
NF-κB signaling protects against development of disease, at least in part, through reduced 
expression of cytokines that are transcriptional targets of NF-κB [30,33,34,38].  Chapter 
IV of this dissertation as well as previous work describe ABIN1 as an important inhibitor 
of NF-κB activation [54,55,59].  It characterizes mice expressing the ubiquitin binding-
deficient mutant, ABIN1[D485N], as prone to spontaneous immune hyperactivation and 
severe GN, which is frequently fatal by 6 months [53,184].  The work outlined in Chapter 
IV describes a pathogenic state in which ABIN1 fails to inhibit NF-κB stimulation to 
allow rampant hyperactivation and uncontrolled inflammation.  It did not define a 
specific cellular mechanism or tissue-specific interaction which could be a target for 
therapeutic pharmacologic intervention, or allow current therapies to be better targeted to 





The present study used nephrotoxic sera (NTS) containing antibodies directed 
against the glomerular basement membrane (GBM) to induce a well-characterized model 
of nephrotoxic nephritis (NTN).  NTS-induced damage in wild-type and ABIN1[D485N] 
mice is used to address the hypothesis that NF-κB-dependent proinflammatory mediator 
production by intrinsic renal cells, particularly podocytes, contributes to initiation and 
progression of GN through enhanced retention and activation of neutrophils. The model 
of acute NTN mimics the pathogenesis of a number of human glomerular diseases, 
including lupus nephritis and rapidly progressive GN, and anti-GBM GN is associated 
with in vivo activation of NF-κB [38,185]. This chapter describes a role for glomerular 
cell ABIN1 regulation of NF-κB in antibody-mediated GN, and we describe a novel 
pathogenic interaction between podocytes and neutrophils within the glomerulus.    
 
5.2 – Results 
 
ABIN1[D485N] mice exhibit exaggerated and localized renal disease compared to 
WT 
Chapter IV describes that ABIN1[D485N] mice spontaneously develop severe 
GN beginning at 3-4 months of age that progresses by 5-6 months [184].  To define the 
effects for this ABIN1 mutation on intrinsic glomerular cells, NTS-induced injury was 
induced at 6 weeks of age, immediately after weaning.  Figure 20 shows urine 






Figure 20 – ABIN1[D485N] Mice More Sensitive to NTS than WT. 
NTS administered to mice at 6 weeks of produces significantly different levels of 
proteinuria, with ABIN1[D485N] animals exhibiting 9x the level of urine albumin.  
Normal serum (NS) served as a control and did not induce proteinuria.  Injection of ontrol 
sera (NS), did not change proteinuria in either WT or ABIN1[D485N] mice.  (n = 6-12 







just prior to NTS tail vein injection (0 hour) and 24 hours after NTS injection.  The 0 
hour UAC of WT and ABIN1[D485N] mice were not different, and administration of an 
equal amount of normal serum immunoglobulin did not increase the 24 hour UAC above 
unstimulated levels in either WT or ABIN1[D485N] mice.  Both WT and 
ABIN1[D485N] mice demonstrated a significant increase in UAC 24 hours after NTS  
administration, but the increase in UAC was 9-fold higher in ABIN1[D485N] mice 
compared to WT mice.   
To separate the effects of ABIN1[D485N] on systemic immune activation and on 
intrinsic renal cells, NTN was induced in chimeric mice, as described in materials and 
methods.  Figure 21 shows that NTS-induced proteinuria was similar in WT mice 
whether transplanted with WT or ABIN1[D485N] mouse bone marrow. Again, as shown 
in Figure 20, ABIN1[D485N] mice showed significantly greater albuminuria than wild-
type mice, and that proteinuria was similar in ABIN1[D485N] mice transplanted with 
WT or ABIN1[D485N] mouse bone.  Thus, differences in proteinuria in chimeric mice 
were due to the host genotype, not to the immune system genotype. This conclusion was 
supported by serum expression of common immune mediators. Figure 22 shows that no 
significant differences between WT and ABIN1[D485N] mice in serum levels of G-CSF, 
GM-CSF, IL1α/β, IL2, IL3, IL4, IL5, IL6, IL12p70/p40, TNF-α,  KC, MCP-1, MIP1α/β, 
or RANTES were observed.   
To examine the local glomerular inflammatory response to NTS, the number of 
CD45 and myeloperoxidase (MPO) positive leukocytes infiltrating glomeruli was 
determined at 2 hr and 24 hr after NTS administration by immunohistochemistry (IHC). 







Figure 21 - Bone Marrow Transplant Suggests Host Genotype is an Important 
Factor in Response to NTS 
Bone marrow transplant using ABIN1 WT hosts and either WT or ABIN1[D485N] bone 
marrow (n=10 each) produced no change in proteinuria at 13 weeks 24 hours post-NTS.  
Likewise, ABIN1[D485N] hosts did not respond differently due to immune genotypes 
(n=5 each), however the host genotype was related to a significant change in proteinuria 
severity following NTS administration.  ANOVA was used to compare values between 
the 4 conditions.   








Figure 22 - Serum Cytokine Analysis of WT and ABIN1[D485N] Mice before and 
following NTS 
Serum cytokine expression was relatively unchanged between ABIN1 WT and 
ABIN1[D485N] animals. Black corresponds to lower relative expression and increasing 
red corresponds to increasing expression of an individual cytokine within the four 
conditions.  (n = 4 per condition) 







in neutrophil azurophilic granules, modestly expressed in monocyte lysosomes, and lost 
from tissue macrophages[186].  At 2 hours, WT mice expressed an average (± 95% 
confidence interval) of 1.44 (±0.28) CD45 positive cells per glomerulus while 
ABIN1[D485N] mice had 2.31 (±0.12) (Figure 23).  At 24 hours, WT mice glomeruli 
decreased to 1.10(±0.36) CD45 positive cells per glomeruli while ABIN1[D485N] 
increased slightly to 2.33 (±0.29) cells per glomeruli (Figure 23).  Likewise, WT mice at 
2 hours expressed 0.60 (±0.13) MPO positive cells per glomerulus while ABIN1[D485N] 
mice had more than twice the MPO positive cells with 1.34 (±0.19) (Figure 23).  At 24 
hours, MPO positivity of WT mice glomeruli descreased to 0.23 (±0.11) MPO positive 
cells while ABIN1[D485N] maintained 0.95(±0.35) cells per glomeruli (Fig. 1e, p > 
0.05).  Representative images are shown in Figure 24.  
Structural and ultrastructural characteristics of NTS challenged ABIN1[D485N] 
and WT mice were assessed by light microscopy, transmission electron microscopy 
(TEM), and WT-1 IHC. Blinded analysis of Periodic acid–Schiff (PAS) stained kidney 
sections showed no differences in mesangial cellularity between WT and ABIN1[D485N] 
mice that received control serum or NTS  (n=5 per condition) (Figure 25 and Figure 26).  
Mesangial matrix was significantly increased only in ABIN1[D485N] mice that received 
NTS. Endothelial cell and podocyte changes were assessed using TEM (Figure 27).  
Endothelial cells show a typical ultrastructure without obvious signs of pathology.  
Podocytes showed prominent foot process effacement and slit diaphragm loss that was 
diffuse in ABIN1[D485N] mice, but focal in WT mice.  Glomerular expression of the 






Figure 23 - CD45-positive and MPO-positive Cell Influx into Glomeruli 
Immunohistochemistry was used to assess influx of general leukocytes (CD45+ cells) and 
neutrophils with other minor staining (MPO+ cells) at both 2 hours and 24 hours post 
NTS administration.  The result was increased CD45 and MPO staining at both time 
points for ABIN1[D485N] expressing mice.  (n = 4-5 per condition and 30 glomeruli per 









Figure 24 - Representative Images for Immune Cell Influx into Glomeruli Post-NTS 







Figure 25 – Histological Analysis of PAS-stained Sections 
Blinded analysis of PAS-stained sections of mouse kidney cortex 24 hours following 
administration of either NS or NTS found only minor differences.   All conditions were 
statistically identical to ABIN1 WT animals given control serum (NS), with the exception 
of a slight elevation of matrix expansion in ABIN1[D485N] mice treated with NTS.  (n = 
5 per condition with 30 glomeruli counted per sample.)  Student’s T-test compared values 
between two groups. 







Figure 26 - Representative Images for Histological Analysis of Glomeruli Following 
NTS 
These representative images provide examples of what was described in Figure 25. 








Figure 27 - Ultrastructural Analysis of NTS-induced Changes to Glomerular 
Basement Membrane 
Changes to the glomerular podocyte were noted 24 hours following NTS administration.  
(a) TEM of ABIN1 WT glomeruli 24 hours post-NTS showed minor foot process 
effacement.  (b) ABIN1[D485N] mice show massive foot process effacement at 24 hours 
post-NTS.  Representative images highlight this discrepancy.  Endothelial cell changes 
and basement membrane thicken were not widespread.  Scale bar represents 500nm.   





corresponds to increased proteinuria and worsening renal function[187].  Figure 28 shows 
a significant reduction in WT-1 stained nuclei per glomerular section in ABIN1[D485N] 
mice, compared to WT, both at endogenous levels using normal sera as well as 24 hours 
following anti-GBM administration.  Representative images are shown in Figure 29. 
To determine production of mediators of inflammation by glomerular cells, 
glomeruli were purified from renal cortex by sieving, RNA was extracted, and expression 
levels of specific transcripts were determined using a custom qRT-PCR analysis.  Genes 
included in this analysis were documented previously as contributing to GN either 
directly or as biomarkers and included adhesion molecules (VCAM1, ICAM1), 
profibrotic/proinflammatory mediators (TGFβ1, C1qB, C3, CD74, EGF), interferons 
(IFNα1, IFNγ), chemokines and cytokines (MCP-1, CCL5, CXCR7, TNF-α, IL1α, 
IL12b, IL17a), cytoskeletal/matrix proteins (MYH9, MMP2, MMP7, TIMP2), or NF-κB 
pathway proteins (RELa, NF-κBiα, IRAK1, NF-κBiζ, NF-κB1).  Figure 30 displays the 
differences in glomerular gene expression between WT and ABIN1[D485N] mice 24 
hours after NTS administration.  mRNA expression of a number of proinflammatory 
cytokine and adhesion proteins was significantly increased in ABIN1[D485N] mouse 
glomeruli.  Matrix metalloproteinase 7 (MMP7) exhibited a 40-fold increase in 
ABIN1[D485N] mouse glomeruli, compared to WT.  Other notable anti-GBM-induced 
increases in ABIN1[D485N] mouse glomeruli included VCAM1 (3.00 fold), IL1α (13.21 
fold),  IL17α (2.14 fold), TNF-α (5.88 fold), CCL2/MCP-1 (1.97 fold) and EGF (1.98 








Figure 28 – WT1-staining per Glomeruli 
Wilms Tumor 1 (WT1) is a nuclear marker of mature podocytes.  Glomerular WT1 
staining following control (NS) or NTS treated animals represents podocyte loss.  
ABIN1[D485N] mice exhibited a lower WT1 positive cell count per glomeruli than 
ABIN1 WT under either control or damaged conditions.  (n = 4 per condition, with 30 
glomeruli counted for each sample)  Bars represent SEM.  T-test was used to compare 







Figure 29 - Representative Images for WT1 Staining 
These representative images provide examples of what was described in Figure 28. 







Figure 30 – Expression of Proinflammatory Markers from Isolated Glomeruli from 
WT and ABIN1[D485N] Mice 
Isolated glomeruli from WT or ABIN1[D485N] kidneys showed marked transcriptional 
changes in a number of proinflammatory cytokines, chemokines and adhesion molecules.  
GAPDH served as a housekeeping gene and Student’s T-test was used to compare 
between two groups.  (n = 4 per condition) 







Loss of ABIN1 ubiquitin binding function in podocytes results in excess production 
and secretion of NF-κB targeted proinflammatory mediators.  
Previous studies suggested NF-κB activation plays a role in development of GN 
and in podocyte dysfunction [30,33,34,38,184].  To determine if ABIN1 regulates NF-κB 
activation and proinflammatory responses in podocytes, changes in NF-κB-dependent 
gene expression were assessed in WT and ubiquitin binding null ABIN1[D472N] 
expressing podocytes following 3-hour stimulations with TNF-α.  The array assessed NF-
κB target genes categorized as chemokines or cytokines (27), inflammatory markers (33), 
immune mediators (30).  Figure 31 shows that proinflammatory NF-κB target gene 
expression was upregulated in ABIN1[D472N] podocytes.  Those findings were 
confirmed using single target RT-qPCR for notable genes involved in GN pathogenesis, 
including MCP-1 (CCL2), IL-8, CSF2 (GM-CSF), and CSF3 (G-CSF), and significant to 
at least p<0.01 at every time point (Figure 32).  Target gene expression in 
ABIN1[D472N] podocytes was found to be 4-10 fold higher for each target even without 
exogenous stimulation. To confirm that increased transcript results in increased protein 
secretion, podocyte supernatants were collected without contamination by FBS or 
exogenous TNF-α, as outlined in Materials and Methods.  ELISA for MCP-1, IL-8 and 
TNF-α confirmed that increased secretion of these NF-κB regulated proinflammatory 
proteins correlated with increased gene expression in ABIN1[D472N] podocytes (Figure 
33).   
 
Interaction between podocytes and neutrophils in proinflammatory activation and 






Figure 31 - Expression of Proinflammatory Factors in Cultured Podocytes 
RT-qPCR array showed transcriptional changes similar to what was reported in isolated 
glomeruli following a 3-hour stimulation by TNF-α.  Notably, proinflammatory cytokines 
and chemokines were expressed at higher levels in ABIN1[D472N] expressing podocytes 
with or without stimulation.   GAPDH served as a housekeeping gene and Student’s T-
test was used to compare between two groups.  (n = 2 per condition) 








Figure 32 – Single Target RT-qPCR Validation of Array Data 
Validation of four cytokines noted in the array showed significant increases in expression 
using single-target RT-qPCR with stimulation times ranging from 0-6 hours. Expression 
of these targets was shown to be 4-10 fold higher even at basal levels in cells expressing 
ABIN1[D472N].   GAPDH served as a housekeeping gene, all experiments were carried 
out in triplicate.  (n = 3-5 per condition)  All points are significant by Student’s T-test 
between WT and ABIN1[D472N] with p<0.01. 








Figure 33 - ELISA Quantification of Secreted Cytokines from Cultured Podocytes 
Quantification of secreted proteins by ELISA showed the differences in transcript 
corresponded to increased secretion of cytokines and chemokines into the cell culture 
supernatant. All experiments were completed in triplicate and repeated at least 3 times.  
Student’s T-test compared values between two groups. (*p<0.05, **p<0.01) 







Figure 23 and Figure 24 show that glomerular leukocyte accumulation is 
enhanced in vivo in ABIN1[D485N] expressing mice following NTN. To determine if 
ABIN1 dysfunction in podocytes was a potential mechanism for enhanced leukocyte 
recruitment into the glomerulus, the ability of WT and ABIN1[D472N] podocyte 
supernatants on chemotaxis of primary human neutrophils was tested (Figure 34).  
Podocytes expressing WT ABIN1 produced a secretome capable of recruiting cells into a 
synthetic membrane when unstimulated, and secretome from WT cells previously 
stimulated with TNF-α increased this effect.  ABIN1[D472N] expressing podocytes 
produced a secretome with stronger chemotactic capabilities than ABIN1 WT expressing 
cells at both basal levels and when stimulated. The ability of podocyte supernatants to 
stimulate neutrophil degranulation in primary human neutrophils was examined by 
measuring plasma membrane CD35 (secretory vesicle marker) and CD66b (specific 
granule marker) expression (Figure 35).  Although podocyte supernatants following 
incubation with TNF-α induced a significant increase in CD35 and CD66b expression, 
there were no differences in degranulation induced by supernatants from WT and 
ABIN1[D472N] podocytes.  
To determine if the increased chemoattraction and degranulation induced by 
podocyte products affected podocyte integrity, the effect of neutrophil granule contents 
on podocyte cytoskeletal morphology was assessed.  Podocytes were cultured for 24 hr 
with supernatants from primary human neutrophils stimulated without (control) or with 
TNF-α/fMLF for 30 minutes, and actin stress fibers were visualized using rhodamine-
phalloidin staining.  Both WT and ABIN1[D472N] podocytes displayed typical healthy 







Figure 34 - Induction of Neutrophil Chemotaxis by Podocyte Cell Culture 
Supernatant 
Chemotaxis of primary human donor neutrophils into synthetic membranes was induced 
by podocyte cell culture supernatant over control cell culture media, and stimulation of 
the podocytes before washing and collection of their media resulted in greater rates of 
chemotaxis.  Furthermore, podocytes expressing ABIN1[D472N] were able to induce 
twice the rates of chemotaxis as ABIN1 WT.  (n = 3 distinct cell culture supernatants per 
condition, each used to stimulated 3 different donors of primary neutrophils.)  Student’s 
T-test compares values between groups.  (**p<0.01) 








Figure 35 - Induction of Neutrophil Degranulation Markers by Podocyte Cell 
Culture Supernatant 
Podocyte cell culture supernatant was able to induce expression of degranulation 
markers, C35 and CD66b, on human primary neutrophils.  No significant differences 
were noted between ABIN1 WT and ABIN1[D472N] podocyte supernatant, although 
podocytes stimulated before washing and collection of supernatant were able to induce 
significant expression of degranulation markers on primary neutrophils.  Expression of 
CD35 and CD66b was quantified by flow cytometry.  (n = 3 distinct cell culture 
supernatants per condition, each used to stimulated 3 different donors of primary 
neutrophils.)  Student’s T-test compares values between groups.  (*p<0.01) 









including long stress fibers extending at least half the length of the cell and crossing the 
nucleus, with a primarily unidirectional distribution (Figure 36).  Anisotropy is a 
measurement of the angularity of the f-actin stress fibers which uses rotational statistics 
to quantify changes to f-actin organization using FibrilTool which utilizes raw images 
and avoids potential bias of reprocessing [84].  Figure 37 shows the anisotropy of WT 
and ABIN1[D472N] podocyte stress fibers.  Anisotrophy was significantly reduced in 
ABIN1[D472N] podocytes, compared to WT.  TNF-α/fMLF stimulated neutrophil 
supernatant caused a significant loss of stress fiber anisotropy compared to control 
supernatant in both WT and ABIN1[D472N] podocytes.  Each cell assessed by FibrilTool 
was also examined for three additional features of podocyte morphologic alteration; 
transnuclear stress fiber loss, ring formation, and actin-rich center (ARC) formation 
(Figure 38).  All three of these features were found to be significantly increased in 
ABIN1[D472] podocytes exposed to stimulated neutrophil granules, compared to WT. 
Multivariate logistical regression analysis produced odds ratios of 7.00, 3.87, and 3.85 for 
transnuclear fiber loss, ring formation, and actin rich center (ARC) formation, 
respectively, in ABIN1[D472] podocytes (Figure 39).   
 
 
Inhibition of neutrophil degranulation reduces proteinuria in vivo 
The altered podocyte cytoskeleton induced by supernatants from stimulated neutrophils 
and the ability of supernatants from stimulated podocytes to induce neutrophil 
degranulation suggested that release of granule neutrophil contents participates in 






Figure 36 - Neutrophil Granules Induce Cytoskeletal Remodeling in Cultured 
Podocytes 
Neutrophil granules were shown to induce major cytoskeletal remodeling of cultured 
podocytes.  Representative images of rhodamine-phalloidin stained f-actin show parallel 
stress fibers in podocytes exposed to supernatant from unstimulated neutrophils, but loss 
of both length and orientation of these stress fibers upon 24 hour exposure to supernatant 
from TNF-α-fMLF stimulated neutrophils.   






Figure 37 - Anisotropy of Podocyte F-actin Following Exposure to Neutrophil 
Granules 
The loss of stress fiber orientation is quantified using Fibriltool as described in the 
Chapter 2.  The anisotropy of f-actin was significantly reduced by exposure to neutrophil 
(PMN) granules and also in podocytes expressing ABIN1[D472N] (n=3 samples  per 
condition with at least 30 cells analyzed per sample). 







Figure 38 - Assessment of Common Morphogenic Pathologic Changes in Podocyte 
Cytoskeleton 
Other commonly cited morphological changes assessed were loss of transnuclear stress 
fibers, ring formation and ACR formation.  Representative images for each are given.  
All experiments were completed in triplicate with at least 3 separate experiments 
performed.  Multivariate logistic regression analysis was used to compare dichotomous 
outcomes of actin remodeling and accounted for both ABIN1 genotype and exposure to 
granules. 








Figure 39 - Odds Ratio of Genetic Effect and Neutrophil Granules on Pathologic 
Podocyte Cytoskeletal Rearrangements 
To properly separate the dichotomous outcomes resulting from the stimulus (neutrophil 
granules) versus the ABIN1 genotype, multivariate logistic regression analysis was used 
to odds ratios and clearly showed an impact of each on podocyte actin remodeling.   








unique TAT-SNAP-23 fusion protein to inhibit neutrophil degranulation in vivo [89,188–
190]. Both WT and ABIN1[D472N] mice treated with TAT-SNAP-23 at the time of  
anti-GBM administration and 6 hours later showed a significant reduction in proteinuria 
at 24 hours (Figure 40a).  Although the absolute levels of proteinuria were higher in both 
groups of ABIN1[D472N] mice, compared to WT, the fold reduction in proteinuria as a 
response to TAT-SNAP-23 treatment was significantly lower in ABIN1[D485N] mice 
compared to WT (Figure 40b). 
 
 
5.3 – Discussion 
 
 In the past few years, ABIN1 has emerged as a novel physiological inhibitor of 
NF-κB and a genetic factor in autoimmunity and glomerulonephritis (GN), but a 
mechanistic role for ABIN1 function in GN had not been characterized [53,66,184].  In 
this study, we show that transgenic disruption of ABIN1 polyubiquitin binding activity 
(by mouse D485N and homologous human D472N mutation) results in enhanced 
podocyte injury and proinflammatory neutrophil activation following administration of 
nephrotoxic sera (NTS) containing antibodies directed against glomerular basement 
membrane (GBM) in mice and proinflammatory activation of cultured human-derived 
podocytes.  The current paradigm is that GN is initiated from glomerular immune 
complex deposition, followed by proinflammatory activation by podocytes and other 
glomerular cells, however events regulating intrinsic kidney effects are comparatively 






Figure 40 - TAT-SNAP23-mediated Inhibition of Neutrophil Degranulation Reduces 
Proteinuria 
Inhibition of neutrophil degranulation in vivo reduces proteinuria due to NTS.  (a) 
Administration of TAT-SNAP23 at 0 hours and 6 hours following administration of NTS 
markedly reduces proteinuria in ABIN1 WT expressing animals, but this reduction is 
muted in mutant animals. (n=6-9 per condition) (b) Fold change reduction in average 
UAC following TAT-SNAP23 treatment was higher in WT mice than in ABIN1[D485N] 









indicate that immune deposition is mediated by autoantibody reactivity to endogenous 
and planted target glomerular antigens [5,192–195].  While it is presumed that these 
autoantibodies are nephritogenic, to date no pathogenic mechanisms have been defined.  
The NTS in vivo model was selected for our study for three reasons: (1) reports show 
glomerular NF-κB activation, (2) it shares the etiology of an important type of human 
GN without the requirement of presensitization of the immune system, and (3) rapid or 
acute development of proteinuria in response to NTS injection may allow investigation of 
the instigating pathogenic mechanism of podocyte injury [38,185,196].  Consistent with a 
podocyte injury postulate, we report no remarkable mesangial cell alterations, including a 
lack of mesangial cell expansion post NTS injection for both WT and ABIN1[D485N] 
mice and only minimal matrix expansion.  There was, however, focal podocyte foot 
process effacement in WT kidneys on electron microscopy which was more pronounced 
in ABIN1[D485N] mice.  Loss of glomerular WT-1 staining further supported podocyte 
dysfunction in α-GBM-mediated GN.  Urinary protein loss was more severe in 
ABIN1[D485N] mice following administration of α-GBM.  Proteinuria which was 9-fold 
higher in ABIN1[D485N] mice compared to WT and there was noted enrichment of 
CD45+ cells (leukocytes) and MPO staining (neutrophil azurophilic granules) in 
glomeruli of NTS treated ABIN1[D485N] mice compared to WT at both 2 hours and 24 
hours following NTS administration.  Interestingly, neutrophils were retained in the 
glomeruli at 24 hours to a much greater degree in ABIN1[D485N] mice than in WT 
which suggests either the immune system itself was mounting a stronger reaction to the 
NTS or something within the local tissue was acting on resident neutrophils and other 





of increased immune activation vs local tissue effects, bone marrow transplant produced 
chimeric mice and showed no effect of immune system genotype on the severity of GN 
resulting from NTS and instead suggested that the local genotype was indeed the driving 
force behind increased severity of renal dysfunction in ABIN1[D485N] mice.  
Differences between reactivity between 6-week old mice and 12-week old mice post bone 
marrow transplant were as expected and the well-described response of C57BL/6 mice to 
NTS allowed controlled glomerular damage that was neither the extreme nor the subdued 
categories of responses [197,198].  These findings indicated that glomerular loss of 
ABIN1 polyubiquitin binding function promotes autoantibody-mediated injury and 
proteinuria and suggests podocytes may be a cause rather than an effect of these 
pathogenic changes.  The potential mechanism for α-GBM-induced injury likely involves 
both immune and intrinsic renal tissues, but the mechanism behind their interaction is not 
well understood.  Thus we sought to describe the functional mechanism for α-GBM-
mediated injury using complementary in vivo, in vitro, and ex vivo techniques. 
Glomerular immune cell infiltration and inflammation described above are 
hallmarks of GN.  Going back to the 1990s, studies have shown correlation of elevated 
glomerular expression of NF-κB-regulated proinflammatory mediators MCP-1, TNF-α, 
and IL-1α with progression of GN in rodents and humans [199,200].  Renal cortex has 
previously been used to investigate renal expression changes of proinflammatory genes, 
but cortex samples will contain 70-90% tubule cells and their associated mRNA 
transcript, which would dampen early changes in a glomerulocentric injury like α-GBM-
induced nephritis.  Thus, we performed RT-PCR analysis for NF-κB target and GN-





of many proinflammatory and chemotactic transcripts, including TNF-α, MCP-1(CCL2), 
and IL-1α in ABIN1[D485N] mice 24 hours after NTS injury.  TNF-α is commonly 
overexpressed in both serum and urine of GN patients and correlates to disease severity, 
specifically in immune-complex GN, and podocytes can both produce and respond to 
TNF-α through the NF-κB pathway [201–206].  Thus, TNF-α was utilized as a stimulant 
to study inflammation and podocyte function relating to GN pathogenesis and ABIN1 
function in vitro using human-derived cultured podocytes.  Mirroring the in vivo findings, 
podocytes expressing the homologous human ABIN1 ubiquitin binding mutation 
(D472N) exhibit exacerbated NF-κB activation, increased MCP-1, CSF 1/2, and IL-8 
mRNA expression, and amplified secretion of MCP-1, IL-8, and TNF-α. 
The glomerulus has been shown to be unique among capillary beds in its ability to 
recruit and retain leukocytes, allowing intrinsic renal cells a unique opportunity for 
intimate interaction with immune cells, specifically neutrophils [28].   An intrarenal role 
for neutrophils in the pathogenesis of human GN is implicated by their glomerular 
accumulation in kidney biopsies from patients with various type of GN (including 
MPGN, ANCA, LN and α-GBM disease) and inversely by reduction in disease 
phenotypes with neutrophil depletion in various animal models of GN [3,207,208].  
However, mechanisms for glomerular recruitment and retention of neutrophils and 
neutrophil-directed injury causing proteinuria in GN have not been resolved.  The 
secretome of ABIN1[D472N] expressing podocytes amplified primary human neutrophil 
chemotaxis into synthetic membranes when compared to WT at both unstimulated levels 
and when the podocytes had been previously stimulated with TNF-α.  Furthermore, we 





and secretory vesicles. These granules contain bactericidal proteins that also cause 
inflammatory tissue injury [209,210].  Although ABIN1[D472N] supernatant tended to 
produce higher levels of degranulation markers in neutrophils than WT at endogenous 
levels, this failed to achieve statistical significance.  It was, however, clearly shown that 
stimulated podocytes of either genotype are able to produce a secretome capable of 
degranulating primary neutrophils. Thus, podocytes have the ability to both recruit 
neutrophils to the glomerulus and subsequently activate their release of injurious granule 
contents. To further explore this mechanism in vivo, we utilized an inhibitor of neutrophil 
degranulation, the chimeric protein TAT-SNAP23, which competitively binds complexed 
vesicular fusion proteins, vesicle-associated membrane protein-2 and syntaxin-4, to block 
release of granules from neutrophil cytosol [188,189].  Inhibition of neutrophil 
degranulation by TAT-SNAP23 resulted in marked decreases in α-GBM-mediated 
proteinurea in both WT and ABIN1[D485N] expressing mice.  It was interesting to note 
that TAT-SNAP23 pretreatment of WT mice resulted in a 9.5-fold reduction in UAC 
while ABIN1[D485N] mice only exhibited a 2.6 fold reduction.  This is further evidence 
that the genotype of the intrinsic renal cells, specifically podocytes, is an 
underappreciated pathogenic factor in glomerular maintenance and protection from 
immune-mediated damage.   
The interaction between podocytes and neutrophils is not one-sided and proper 
ABIN1 function within podocytes was shown to be of great importance for limiting 
pathogenic podocyte responses following an insult.  Actin regulation is paramount in slit 
diaphragm maintenance and renal function, and disorganization of actin stress fibers is a 





remodeling of cultured podocyte actin fibers shown by a reduction in the anisotropy of 
podocyte actin fibers, as ABIN1[D472N] expressing podocytes exhibited stress fibers 
which were significantly less organized than WT when subjected to either control 
neutrophil supernatant (no or few granules) or neutrophil supernatant fully degranulated 
by 30 minute exposure to TNF-α/fMLF (high granule concentration).  Furthermore, 
additional metrics of podocyte cytoskeletal rearrangement reinforced the anisotropy 
findings, including loss of transnuclear stress fibers, ring-like actin formation, and ARC 
formation [214,216–219].  Multivariant logistical regression of phenotype frequency was 
used to determine statistical certainty of the dichotomous outcome and clearly showed 
that podocytes expressing ABIN1[D472N] were more likely to produced aberrant actin 
structures under control conditions and that development of these structures was even 
more frequent following 24 hours of exposure to a degranulated neutrophil supernatant.  
In total, actin rearrangement was strongly associated to ABIN1 genotype in cultured 
podocytes in a way that induced pathologic changes, both under stress and at baseline, 
which would promote a greater propensity for worsening disease both before and after a 
nephrotoxic insult.   
When considering that podocytes can both recruit and activate neutrophils and 
that they undergo pathogenic responses as a result of exposure to granules released by 
activated neutrophils, there is clearly support for a mechanism of GN involving a 
podocyte-neutrophil axis of pathological interactions which promote proteinurea and 
worsening renal function.  Furthermore, functional ABIN1 seems to be important in the 
regulation of podocyte responses to inhibit the damaging activity of this proinflammatory 





neutrophil recruitment and activation through proinflammatory signaling within 
podocytes expressing aberrant ABIN1.  These pathogenic processes described above 
represent a shift from the current paradigm of GN pathology shown in Figure 4. The 
findings of this dissertation are outlined graphically in the form of a healthy glomerulus 
(Figure 41) and an inflamed glomerulus (Figure 42) and aim to show the importance of 
podocytes in the pathogenesis of GN.   
In closing, there is growing evidence for intraglomerular NF-κB activation and 
genetic variation in the upstream NF-κB inhibitor ABIN1 in the pathogenesis of GN 
[33,34,53,184,220,221].  Current treatment for GN involves systemic administration of 
large doses of corticosteroids, immunosuppressive drugs, and/or biologic agents. Those 
drugs are successful in inducing a remission of disease in only about 50% of patients, and 
those drugs are associated with significant side effects [222,223].  Our findings in this 
report support a role for disrupted ABIN1-mediated NF-κB activity within podocytes in 
the proinflammatory activation and injury commonly described in GN.  This indicates a 
plausible therapeutic impact for the development of a kidney-targeted NF-κB inhibitor, 
especially for treatment of GN patients with genetic variants for ABIN1 or other NF-κB 
regulators.   We also show that a peptide inhibitor of neutrophil degranulation impeded 
the development of proteinuria in an acute model of immune complex-mediated GN, 








Figure 41 - Healthy Glomerular Capillary 
This diagram represents the glomerular capillary in a healthy glomerulus.  Podocyte foot 
processes are evenly spaced with well-defined slit diaphragms and the entire glomerular 
basement membrane is enveloped in foot processes.  Neutrophils patrol the glomerulus 
constitutively but are not activated. 







Figure 42 - Inflamed Glomerular Capillary 
This diagram represents the proposed pro-inflammatory podocyte-neutrophil axis in the 
pathogenesis of glomerulonephritis.  Antibody-mediated injury is augmented by NF-κB-
directed inflammatory injury in the glomerulus which includes neutrophil chemotaxis, 
activation and degranulation, podocyte foot process effacement and shedding, leaving 
bare GBM, and pseudocyst formation. Our findings suggest that these injurious events 
are mediated by loss of podocyte ABIN1 ubiquitin binding activity ensued by genetic 
variants.   











 This work describes a novel and underappreciated cellular interaction leading to 
glomerulonephritis and describes the molecular mechanism by which it occurs.  It reveals 
that podocytes are not the passive victims of glomerular injury as they have long been 
described.  Podocytes are integral players within the glomerulus and have the ability to 
orchestrate changes in the molecular microenvironment which affect both themselves and 
the kidney as a whole.  Mechanistically, this work shows an important role of ABIN1 as a 
critical inhibitor of NF-κB in glomerular disease, and suggests polymorphisms in ABIN1 
could predispose a patient to a number of diseases involving enhanced NF-κB 
stimulation.  And finally, it has shed light on early changes which occur following 
glomerular damage which initiate later pathology.  Early recognition and inhibition of 
these early events may reduce or prevent the development of chronic glomerular disease 
in some patients.   
 It is my hope that this work will inspire future study in the function of ABIN1, 
glomerular disease and the potential for target tissues to provide inflammatory control 
mechanisms for what have long been thought to be immune-mediated diseases.  To 
facilitate the development of subsequent projects, I have described in detail the beneficial 





specifically how it was used in this project to identify physiologically important proteins 
from complex samples.  Although in vivo models invariably present the most 
physiologically accurate data pertaining to any physiological process, it can be 
overwhelmingly difficult or impossible to obtain pure samples from single-cell 
populations.  The combination of in vitro experimentation with relatively unbiased 
analysis methods can elucidate the importance of low abundant factors in disease that 
would certainly be lost among the noise of a more complex system.   
 Looking beyond this work, there are specific areas of study I hope to promote 
through the publication of this dissertation.  The history of ABIN1 following its initial 
discovery and progressing into transgenic mouse models highlighted the complexity and 
promiscuity of ABIN1 as a ubiquitin binding protein.  A list of ABIN1 interacting 
partners is likely vast, and will need to be identified within individual cell types before 
we may begin to understand the full influence ABIN1 has on human disease and 
homeostasis.  Even when looking specifically at one cytokine (TNF-α) as it stimulates 
one specific pathway (NF-κB), there are three different polyubiquitin linkages interacting 
involving multiple proteins, all of which have different roles and all of which become 
possible targets of ABIN1 binding.  When considering the cell as a whole which may 
contain thousands of proteins regulated by ubiquitin binding, the potential of ABIN1 
activity in any cell type becomes immense.  Future studies can begin by using 
coimmunoprecipitation of ABIN1 and its interacting partners followed by identification 
using LC-MS/MS.  Tissue specific polymorphisms exhibiting increased risk of disease, 
as described in the GWAS study in Chapter 4, highlight promising initial directions for 





pathways which harbor potent targets for precise and high affinity small-molecule 
therapeutics to treat disease only in the target tissue type, which could reduce off-target 
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2002-2006 Gross Human Anatomy Instructor and Lab Coordinator, Missouri 
State University 
              
AWARDS:  
2nd Place Overall, University of Louisville, Research! Louisville, 2015. 
American Society of Nephrology, Kidney STARS Program and Travel Award, 2014. 
American Heart Association, Predoctoral Fellowship, 2014-2016. 
Finalist, Poster Competition, University of Louisville, Research! Louisville, 2014. 
University of Louisville, Research Committee Travel Award, March 2014. 
1st Place, Graduate Research Competition, Cellular and Molecular Biology, Kentucky 
Academy of Sciences Annual Meeting, Morehead State University, November 2013.   
Finalist, Poster Competition, University of Louisville, Research! Louisville, 2013. 
1st Place, Overall Poster Competition, University of Louisville, Biochemistry and 
Molecular Biology Research Colloquium, 2013. 
Michael Gordon Fellowship Awardee, 2013. 
 










Ryan Sheehan, M.S. is a current Ph.D. student in Biochemistry and Molecular Biology 
that completed a rotation in the Powell lab Fall Semester 2012.  Ryan has now joined the 
lab and is working toward developing an independent project.  I have trained him in lab 
techniques for cell culture, protein purification, western blotting, RT-qPCR, and other 
techniques.   
 
Rachel G’Sell, M.S. was a Masters student in Biochemistry and Molecular Biology that 
completed a rotation in the Powell lab Fall Semester 2012.  She joined the lab and 
completed a masters project before moving to the University of Missouri to begin a 
physical therapy program.  I have trained her in lab techniques for cell culture, protein 
purification, western blotting, RT-qPCR, ELISA, immunofluorescence, and other 
techniques.   
 
Rebecca Oliver, B.S. was a summer research undergraduate student in the Powell Lab in 
2012. 
 
Dawn Caster, M.D. is a Nephrology Attending in the Kidney Disease Program at the 
University of Louisville School of Medicine that has completed a one-year research 
fellowship (7/2012-7/2013) in the Powell lab and is now starting a clinical/translational 
research program in glomerular disease. 





Katie Harris was a middle school student at St. Francis of Assisi who completed an 8th 
grade science project under my guidance which won local, regional and Kentucky State 
science fairs. 
 
Rose Chancy is a middle school student at St. Francis of Assisi who completed her 7th, 
8th and 9th grade science projects under my guidance which won local and regional 
science fairs and placed second at the Kentucky State science fair in 2012 and first place 
in 2013 followed by a top 30 finish nationally.   
 
COMMUNITY SERVICE:  
2012-2014  Judge – Manual Regional Science Fair (grades 9-12)   
2012-2013  Judge – St. Francis of Assisi Science Fair 
2012   Judge – Kentucky Orchid Society Annual Show  
 
PROFESSIONAL MEMBERSHIPS:  
American Heart Association 
American Society of Nephrology 
Kentucky Academy of Sciences  
American Association for the Advancement of Science 
American Society for Biochemistry and Molecular Biology 







ADMINISTRATIVE SERVICE:  
 
Biochemistry and Molecular Biology Student Body President 
Biochemistry and Molecular Biology Student Body Vice President 
University of Louisville School of Medicine Strategic Planning Steering Committee 
Graduate Executive Committee 
Council of the School of Medicine 
Department of Microbiology and Immunology Chair Search Committee 
Interviews with Department of Biochemistry and Molecular Biology Graduate School 
Candidates 





2013-2016  Derby City Mustang Club 
2011-2014  Kentucky Orchid Society 
2010-2016  Louisville Metro Government Kickball League 
2010-2012  Louisville Masters Swim Team 
2002-2003  Varsity Swimming Captain 
2001, 2003  All-Conference, Men’s Swimming 
1999-2003  Varsity Swimming and Diving Team 










Granting Agency: American Heart Association (Predoctoral Fellowship, 
14PRE19880002) 
Period of Performance:  07/01/14-06/30/16 
Title: ABIN1 function in the protection from lupus nephritis and cardiovascular disease 
PI: Erik Korte  24 Cal. Months (90% effort)  $52,000 
The overall objective of this project is to define the role of ABIN1 in renal cells in the 







“ABIN1, Podocytes and the Glomerular Inflammatory Microenvironment”. University of 
Louisville, Department of Biochemistry and Molecular Biology Seminar Series. 






“ABIN1, Podocytes and the Glomerular Inflammatory Microenvironment”. University of 
Louisville, Kidney Disease Program Research Seminar Series. (September 9th, 2015) 
 
“ABINI and Lupus Nephritis: Why the Kidney Matters”. University of Louisville, 
Department of Biochemistry and Molecular Biology Seminar Series. (May 12th, 2014) 
 
“ABIN1 and Lupus Nephritis: Why the Kidney Matters”. University of Louisville, 
Kidney Disease Program Research Seminar Series. (April 18th, 2014) 
 
“ABIN1 Dysfunction as a Basis for Lupus Nephritis”. Kentucky Academy of Sciences, 
Morehead State University, 2013. (November 9th, 2013).  1st Place, Cellular and 
Molecular Biology. 
 
“ABIN1 Dysfunction as a Basis for Lupus Nephritis”. University of Louisville, 
Biochemistry and Molecular Biology Research Colloquium, 2013. (August 23rd, 2013)  
 
“Ubiquitin Binding by ABIN-1 Controls Inflammation and Development of Lupus 
Nephritis”. University of Louisville, Kidney Disease Program Research Seminar Series. 
(April 18th, 2013) 
 
“Ubiquitin Binding by ABIN-1 Controls Multiple Signaling Pathways”. University of 







 “B7 Costimulation Blockade in Induced Allograft Tolerance”. University of Louisville, 





National/International Conferences  
 
 
Powell DW, Sheehan RM, Caster DJ, McLeish KR, Korte EA. A novel mechanism for 
enhanced neutrophil recruitment, retention, and podocyte damage in immune complex-
mediated glomerular disease. American Association of Immunology Meeting, Seattle, 
Washington , May 2016 
 
Korte, EA; Sheehan, RM; Powell, DW. Loss of glomerular cell ABIN1 polyubiquitin 
binding results in enhanced pro-inflammatory signaling and kidney injury. Abstract and 
Poster Preparation. Mechanisms of Pro-Inflammatory Diseases, Keystone Symposia. 
Olympic Valley, CA, April 2015. 
 
Powell, DW; G’Sell, RT; Sheehan, RM; Caster, DJ; Merchant, ML. McLeish, KR; 





Human Glomerular Cells. Abstract and Poster Presentation, American Society of 
Nephrology Annual Meeting, Philadelphia, PA. November 2014. 
 
Korte, EA, G’Sell, RT; Sheehan, RM; Caster, DJ; Powell, DP.  Dysfunction of 
polyubiquitin binding by ABIN1 as a basis for lupus nephritis.  Abstract and Poster 
Presentation, Experimental Biology International Conference, San Diego, CA, April 
2014. 
 
Caster DJ, Korte, EA, Birmingham DJ, Joglekar AS, Klein JB, Harley JB, Namjou B, 
McLeish KR, Merchant ML, Rovin, BH, and Powell, DW. Patterns of Circulating 
Autoantibodies in Patients with Lupus Nephritis. Abstract and Poster Presentation, 
American Society of Nephrology, Kidney Week, Atlanta, GA, November 2013. 
 
Korte, E.A., Cummins, T.D., Mendenhall, M.D., Barati, M.T., Klein, J.B., and Powell, 
D.W.  Elongin C is a Mediator of Notch4 Activity in Human Renal Tubule Cells.  
Keystone Symposia, Whistler, Canada, March 2012. 
 
Powell, D.W. Korte, E.A., Cohen, P., and Nanda, S.K. Disruption of ABIN1 inhibition 
of NF-κB activity causes lupus-associated glomerulonephritis. Keystone Symposia, 
Whistler, Canada, March 2012. 
 
Caster DJ, Birmingham DJ, Klein JB, Harley JB, Korte EA, McLeish KR, Merchant 





Membranous Lupus Nephritis. American Society of Nephrology Kidney Week, San 





Korte, Erik; Sheehan, Ryan; Caster, Dawn; Powell, David.  Loss of glomerular ABIN1 
polyubiquitin binding results in enhanced pro-inflammatory signaling and kidney injury.  
University of Louisville, Research! Louisville, 2014. 2nd Place Overall, Poster 
Competition. 
 
Korte, Erik; Sheehan, Ryan; Powell, David.  Loss of glomerular cell ABIN1 
polyubiquitin binding results in enhanced pro-inflammatory signaling and kidney injury. 
University of Louisville, Biochemistry and Molecular Genetics Research Colloquium, 
2015. 
 
Korte, Erik; Sheehan, Ryan; Caster, Dawn; G’Sell, Rachel; Powell, David.  Loss of 
ABIN1 Function Results in a Pro-Inflammatory Phenotype in Human Glomerular Cells.  
University of Louisville, Research! Louisville, 2014. Finalist, Poster Competition. 
 
Korte, Erik; Sheehan, Ryan; Caster, Dawn; G’Sell, Rachel; Powell, David.  ABIN1 
Dysfunction as a Basis for Lupus Nephritis. University of Louisville, Research! 






Joglekar AS, Korte, EA, Caster DJ, Klein JB, Rovin BH, Harley JB, Merchant ML, 
McLeish KR, Stribinskis V, G’Sell RT, Sheehan RM, and Powell, DW. Target Antigens 
in Membranous Lupus Nephritis. Abstract and Poster Presentation, Research! Louisville, 
Louisville, KY, September 2013. 
 
Korte, Erik; Sheehan, Ryan; Caster, Dawn; G’Sell, Rachel; Powell, David.  ABIN1 
Dysfunction as a Basis for Lupus Nephritis. University of Louisville, Biochemistry and 
Molecular Biology Research Colloquium, 2013.  1st Place Poster Graduate Student, 1st 
Place Poster Overall. 
 
Korte, E.A., Cummins, T.D., Mendenhall, M.D., Barati, M.T., Klein, J.B., and Powell, 
D.W.  Elongin C is a Mediator of Notch4 Activity in Human Renal Tubule Cells.  
University of Louisville, Biochemistry and Molecular Biology Retreat, 2011. 
 
Caster DJ, Klein JB, Harley JB, Korte EA, McLeish KR, Merchant ML, Oliver R, Rovin 
BH, and Powell DW. Identification of GFRα1 as a Candidate Target Antigen in 




Caster DJ, Korte EA, Merchant ML, Klein JB, Wilkey DW, Rovin BH, Birmingham DJ, 





glomerular annexin A2 identify patients with proliferative lupus nephritis.” Proteomics 
Clinical Applications. 2015 Dec;9(11-12):1012-20.  PMID: 25824007. 
 
D. J. Caster* and E. A. Korte*, S. K. Nanda, K. R. McLeish, R. K. Oliver, R. T. G’sell, 
R. M. Sheehan, D. W. Freeman, S. C. Coventry, J. A. Kelly, J. M. Guthridge, J. A. 
James, K. L. Sivils, M. E. Alarcon-Riquelme, R. H. Scofield, I. Adrianto, P. M. Gaffney, 
A. M. Stevens, B. I. Freedman, C. D. Langefeld, B. P. Tsao, B. A. Pons-Estel, C. O. 
Jacob, D. L. Kamen, G. S. Gilkeson, E. E. Brown, G. S. Alarcon, J. C. Edberg, R. P. 
Kimberly, J. Martin, J. T. Merrill, J. B. Harley, K. M. Kaufman, J. D. Reveille, J.-M. 
Anaya, L. A. Criswell, L. M. Vila, M. Petri, R. Ramsey-Goldman, S.-C. Bae, S. A. 
Boackle, T. J. Vyse, T. B. Niewold, P. Cohen, and D. W. Powell, “ABIN1 Dysfunction 
as a Genetic Basis for Lupus Nephritis,” J. Am. Soc. Nephrol. JASN, 2013 
Nov;24(11):1743-54.  PMID: 23970121. 
   *Equal Contributing First Authors 
 
Korte EA, Gaffney PM, Powell DW. (2011) Proteomic applications for defining cellular 
mechanisms and diagnostic markers of Systemic Lupus Erythematosus. Arthritis 
Research & Therapy.  2012 Feb 20;14(1):204.  PMID: 22364570. 
 
Cummins TD, Mendenhall MD, Lowry MN, Korte EA, Barati MT, Khundmiri SJ, 
Salyer SA, Klein JB, Powell DW. (2011)  Elongin C Is A Mediator Of Notch4 Activity 
In Human Renal Tubule Cells. Biochim Biophys Acta. 1814,1748-1757. 
 
